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ABSTRACT 
Hereditary Spastic Paraplegia (HSP) is a genetic group of neurodegenerative disorders 
characterized by progressive degeneration of corticospinal tracts. Mutations in the 
SPG31 gene, encoding REEP1, are the third most common cause of autosomal 
dominant form of HSP. Recent studies have reported that REEP1, an integral ER 
membrane protein, interacts with the microtubule cytoskeleton to coordinate ER 
shaping. However it precise molecular function is still unknown. 
To better understand the function of REEP1, we generated a model (Drosophila 
melanogaster) for the in vivo analysis of the fly REEP1 homolog (D-REEP1). 
Drosophila and human REEP1 proteins display remarkable homology and conservation 
of domain organization. We analyzed D-REEP1 loss of function and gain of function 
transgenic lines as well as animals expressing pathological forms of the protein. Our in 
vivo data in Drosophila have shown a strong involvement of D-REEP1 in the regulation 
of lipid droplets (LDs) number and size in neuronal and non neuronal tissues. Loss of 
D-REEP1 results in larvae leaner and smaller than their wild type counterparts while 
endoplasmic reticulum membranes are elongated when compared to controls. These ER 
defects are associated with a decrease in lipid droplets number and low triglycerides 
content. On the contrary over expression of wild type D-REEP1 produces a reduction in 
the size of lipid droplets. The lack of animal models available for REEP1 studies and 
experimental data concerning the functional alteration caused by pathological mutations 
of REEP1 prompted to generate transgenic lines carrying D-REEP1 pathological 
mutations and to analyse the consequence of their expression in vivo. Two missense 
mutations (P19R, D56N) affecting the trans-membrane domains of REEP1 and a novel 
mutation (A132V) located in the C-terminal part of the protein have been assessed.The 
mutations in the trans membranes domains relocate REEP1 from the ER to the 
membrane of lipid droplets when expressed in mammalian cells. In vivo expression of 
Drosophila P19R caused oversized LDs in the brain and axons and increased levels of 
triacylgycerides.  
LDs are believed to originate from the endoplasmic reticulum, although the exact 
molecular mechanisms of their biogenesis is still not known. Based on the findings 
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described above and the knowledge about REEP family, we hypothesize that REEP1 
probably play an important role in membrane remodelling and possibly affects the lipid 
droplets metabolism. While, pathological forms of REEP1 could perturb the biogenesis 
and/or turnover of lipid droplets and eventually produce an imbalance in neuronal lipid 
metabolism. 
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RIASSUNTO 
Le Paraplegie Spastiche Ereditarie (HSP) sono un gruppo eterogeneo di malattie 
neurodegenerative, caratterizzate da progressiva spasticità degli arti inferiori, e 
degenerazione del tratto corticospinale. Mutazioni a carico del gene SPG31, codificante 
per la proteina REEP1, sono la terza causa più comune di forme dominanti di HSP. 
Studi recenti suggeriscono che REEP1, una proteina integrale della membrana del 
reticolo endoplasmatico (ER), sia coinvolto nel rimodellamento delle membrane del ER 
attraverso l’interazione con i microtubuli del citoscheletro. Tuttavia la precisa funzione 
biologica e il meccanismo patologica di questa proteina sono ancora sconosciuti. 
Questa tesi ha come oggetto lo studio in vivo della funzione di REEP1 utilizzando come 
organismo modello Drosophila melanogaster. A tale scopo abbiamo identificato 
l’omologo in Drosophila di REEP1 (D-REEP1) e generato delle linee transgeniche per 
la modulazione dell’espressione genica in vivo sia della proteina wild type sia di alcune 
sue varianti patologiche. Analisi in vivo suggeriscono che D-REEP1 sia coinvolto nella 
regolazione del numero e della dimensione dei lipid droplets (LDs) in tessuti neuronali e 
non neuronali.  
L’assenza di D-REEP1 causa una riduzione delle dimensioni larvali e ad un 
allungamento delle membrane del reticolo endoplasmatico. Le alterazioni morfologiche 
del reticolo endoplasmatico sono associate ad una diminuzione del numero totale dei 
LDs e alla riduzione del contenuto dei trigliceridi. Al contrariola sovra-espressione di 
D-REEP1 in vivo induce una riduzione delle dimensioni dei LDs  
La mancanza di studi su organismi modelli e dati sperimentali per valutare le possibili 
alterazioni funzionali causate delle mutazioni patologiche di D-REEP1, ha portato a 
creare delle linee transgeniche di Drosophila per forme mutate di D-REEP1. In tal 
modo si è voluto valutare gli effetti, sia in vivo, che in vitro, di due mutazioni missenso 
(P19R, D56N) localizzate nei domini transmembrana ed una mutazione nuova 
(A132V), non ancora pubblicata, localizzata nella parte C-terminale di D-REEP1. Le 
analisi in vitro hanno dimostrato che le mutazioni situate nei domini transmembrana 
determinano  una alterata localizzazione subcellulare di REEP1. Inoltre, la 
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sovrespressione in vivo di D-REEP1-P19R determina un aumento delle dimensioni dei 
LDs nel sistema nervoso di Drosophila.  
Seppure si ritiene che la biogenesi dei lipidi avviene a livello del reticolo 
endoplasmatico, appare  tuttora sconosciuto l’esatto meccanismo molecolare coinvolto. 
I dati da noi ottenuti e le conoscenze attuali riguardo la famiglia delle proteine REEP 
suggeriscono che, agendo sulla curvatura delle membrane del ER o reclutando 
particolari proteine dei LDs, REEP1 sia probabilmente importante nella generazione dei 
lipid droplets con possibili effetti sul metabolismo lipidico. 
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1. INTRODUCTION 
1.1 HEREDITARY SPASTIC PARAPLEGIA (HSP) 
Hereditary spastic paraplegia (HSP) was first described by Strümpell in 1880 as a 
neurodegenerative disorder. HSP is a genetically and clinically heterogeneous group of 
neurodegenerative disorders with predominant feature the progressive spasticity of the 
lower limbs, associated with mild weakness, and in some cases by urinary urgency and 
subtle vibratory sense impairment (McDermott et al. 2000). The common pathological 
feature of these conditions is retrograde degeneration of the distal portions of the 
corticospinal tracts and the spinocerebellar tracts, which together constitute the longest 
motor and sensory axons of the central nervous system (CNS) (SCHWARZ and LIU 
1956)(Behan and Maia 1974). Clinically these disorders are conventionally subdivided 
into “pure” (or “uncomplicated”) forms, characterized by a progressive spasticity and 
hyperreflexia of the lower limbs, and “complicated” forms in the presence of additional 
neurologic or systemic impairments such as mental retardation, cerebellar ataxia, 
dementia, optic atrophy, retinopathy, extrapyramidal disturbance, epilepsy and motor 
neuropathy (Harding 1993; E Reid 1997). Age of symptom onset, rate of progression, 
and degree of disability are often variable between different genetic types of HSP, as 
well as within individual families. The prevalence of HSP in Europe is estimated at 3–
10 cases per 100 000 population (McMonagle, Webb, and M Hutchinson 2002)(Silva et 
al. 1997). The clinical variability is complicated more by the large genetic 
heterogeneity. HSPs may have autosomal dominant, recessive and X-linked inheritance 
(Table1). To date, 52 loci have been mapped on different chromosomes. Autosomal 
dominant HSP represents about 70% of cases and its mostly characterized by pure 
forms, whereas complicated forms tend to be autosomal recessive (Harding 1993)(John 
K Fink 2003). 
The large number of genes involved complicates the classification of this disorder. 
However the availability of more precise and sophisticated neuroradiological 
investigation techniques, biochemical tests and genetic analysis facilitate the diagnosis 
of familial and sporadic cases. 
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Table 1. HSP genes 
 
Molecular mechanisms underlying axonal degeneration are poorly understood, although 
the studies and analysis of HSP genes have provide insight into HSP pathogenesis. 
Proteins codified by genes known to predispose to HSP, have a biological role in 
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different cellular organelles, this supports the idea that the longest axon of NSC are 
particularly vulnerable to a number of distinct biochemical disturbances.  
At this stage, different molecular processes appear to be involved in different genetic 
types of HSP:  
1) Myelin composition affecting long, central nervous system axons. X-linked SPG2 
HSP is due to proteolipid protein gene mutation, an intrinsic myelin protein (Dubé et al. 
1997). 
2) Embryonic development of corticospinal tracts. X-linked SPG1 is due to mutations in 
L1 cell adhesion molecule which plays a critical role in the embryonic differentiation of 
corticospinal tracts guidance of neurite outgrowth during development, neuronal cell 
migration, and neuronal cell survival (Kenwrick, Watkins, and De Angelis 2000). 
3) Oxidative phosphorylation deficit. Two HSP genes (SPG7/paraplegin and 
SPG13/chaperonin 60) encode mitochondrial proteins (Hansen et al. 2002). Abnormal 
appearing mitochondria (ragged red fibers) and cytochrome C oxidase deficient fibers 
are noted in muscle biopsies of some (but not all) subjects with SPG7/parapegin 
mutation. 
4) Axonal transport. SPG10 autosomal dominant HSP is due to mutations in kinesin 
heavy chain (KIF5A) a molecular motor that participates in the intracellular movement 
of organelles and macromolecules along microtubules in both anterograde and 
retrograde directions (Evan Reid et al. 2002). 
5) Cytoskeletal disturbance. Spastin (SPG4) is a microtubule severing protein whose 
mutations are pathogenic through a disturbance in the axonal cytoskeleton (Errico, 
Ballabio, and Rugarli 2002). 
6) Endoplasmic Reticulum network morphology. The three most common autosomal 
dominant HSPs—SPG3A, SPG4, and SPG31, as well as the less common SPG12 result 
from mutations in proteins directly implicated in the formation of the tubular ER 
network (Park et al. 2010)(Montenegro et al. 2012). 
7) Lipid Synthesis and Metabolism. These latter three HSP proteins, erlin2 seipin and 
spartin, have been directly implicated in biogenesis of lipid droplets (Eastman, Yassaee, 
and Bieniasz 2009; Edwards et al. 2009; Hooper et al. 2010). Although other HSP 
proteins are not directly implicated in LD biogenesis are involved in related lipid and 
cholesterol biosynthetic pathways. SLC33A1 gene (SPG42) encodes the acetyl-CoA 
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transporter that transports acetyl-CoA into the Golgi apparatus lumen. SLC33A1 gene 
has been directly related to the growth of axons because knock down of slc33a1 in 
zebrafish causes defective outgrowth from the spinal cord (Lin et al. 2008). Mutations 
of PNPLA2 gene (SPG39), that encodes neuropathy target esterase protein (NTE), or 
chemical inhibition of NTE, modifies membrane composition and causes distal 
degeneration of long spinal axons in mice and human (Reiter et al. 2001). The 
cytochrome P450-7B1 (SPG5) is involved in the metabolism of cholesterol (Tsaousidou 
et al. 2008). There is currently no “cure” for HSP. Treatment for HSP is limited to 
symptomatic reduction of muscle spasticity through muscle stretching therapy and 
medication for reduction of urinary urgency. Physical therapy accompanying with a 
regular exercise do not prevent or reverse the damage to the nerve fibers, it helps HSP 
patients in maintaining mobility, retaining or improving muscle strength, minimizing 
atrophy of the muscles due to disuse, increasing endurance (and reducing fatigue), 
preventing spasms and cramps, maintaining or improving range of motion and 
providing cardiovascular conditioning. 
1.2  RECEPTOR EXPRESSION ENHANCING PROTEIN 1 (REEP1) 
1.2.1 The SPG31 gene 
Among the loci for pure autosomal dominant HSP (ADHSP) form, three most common 
genes have been identified: SPG4 on chromosome 2p22, which accounts for 
approximately 40% of all pure ADHSP, SPG3A on chromosome 14q11-q21, which is 
responsible for 10% of cases (Zhao et al. 2001) and SPG31 on chromosome 2p11.2 
responsible for 6,5% of the cases (Züchner et al. 2006). Missense mutations and little 
insertions o deletions that cause a reading frameshift, and produce premature stop 
codons, are the most common SPG31 alterations. Splice site mutations and 3’-URT 
sequence alterations have been also reported. (Beetz et al. 2008). 
The SPG31 gene consists of seven exon and four alternative splicing isoforms: 
 Receptor expression enhancing protein 1 (REEP1) isoform 1, is the longest 
isoform (201 aa) encoded by SPG31 gene. Mutations in REEP1 isoform 1 are 
responsible for HSP autosomal dominant form.  
 1. INTRODUCTION 
 
13 
 REEP1 isoform 2 (181 aa), has a distinct and shorter N-terminus, compared to 
isoform 1 and differs in the 5' UTR and 5' coding region. 
 REEP1 isoform 3 (121 aa), has a shorter N.terminus, and differs in the 5' UTR 
and 5' coding region compared to isoform 1. 
 REEP1 isoform 4 (121aa), differs in the 5' UTR and 5' coding region, and lacks 
two alternate exons in the central coding region that causes a frameshift, 
compared to variant 1. The encoded isoform 4 has distinct N- and C-termini and 
is shorter than isoform 1. 
1.2.2 Human REEP1 
The REEP1 gene encodes a protein of 201 amino acids that enclose two putative 
transmembrane domains and a conserved protein domain, TB2/DP1/HVA22, known as 
“deleted in polyposis” domain, with unknown function (Züchner et al. 2006). REEP1 
protein belongs to the REEP/DP1/YOP1 superfamily. Based on the sequence similarity 
this family includes homologues genes from diverse eukaryote species. Members of this 
family form higher-order oligomeric structures. 
 
 
 
Figure 1. Schematic representation of H-REEP1gene 
 
REEP1 is expressed in various non neuronal and neuronal tissues, including spinal cord. 
This follows the now-common finding of almost ubiquitous tissue expression for a 
number of genes that cause distinct neurodegenerative phenotypes. At the subcellular 
level, REEP1 localize to Endoplasmic reticulum membranes as an integral membrane 
protein (Park et al. 2010). Immunostaining experiments have suggested that REEP1 C-
terminal domain is exposed toward the cytoplasm (H. Saito et al. 2004). 
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REEP1 was originally identified as a protein that promotes trafficking of olfactory 
receptors to the plasma membrane surface (H. Saito et al. 2004). Latest studies implies 
that REEP1 protein, as a member of REEPs subfamily (REEP1–4) is involved in ER 
shaping (Park et al. 2010). REEP1 protein, upon over-expression in COS cells forms 
protein complexes with atlasin-1 and spastin, within the tubular ER. Moreover, REEP1, 
can also bind the microtubules and promote ER alignment along the microtubule 
cytoskeleton (Park et al. 2010).  
1.2.3 REEP/DP1/YOP1 Superfamily 
Most species have a number of closely related REEP/DP1/Yop1p superfamily 
members; there are six members in human and other in mammals (REEP1-6), one 
member in S. cerevisia, Yop1p, and one member in barley, H2AV22, (H. Saito et al. 
2004). Systematic analysis of the structure and biochemical properties has shown a clear 
phylogenetic delineation of REEP proteins into two distinct subfamilies, REEP1–4 and 
REEP5–6 in higher species. REEP1–4 subfamily are characterized by the presence of a 
much shorter first hydrophobic segment, the absence of the N-terminal cytoplasmic 
domain, and the presence of a longer C-terminal region comparing to REEP5–6. Even 
species such as Drosophila melanogaster, Strongylocentrotus purpuratus, and 
Caenorhabditis elegans have at least one REEP protein with similarity to each of 
subfamily REEP1–4 and REEP5–6. Different studies, have established a direct role for 
mammalian REEP5/DP1 and yeast Yop1p in shaping endoplasmic reticulum (ER) 
tubules, while the REEP1-4 subfamily is thought to have an important role in ER 
shaping and ER network formation in vitro (Park et al. 2010). 
1.3 THE ENDOPLASMIC RETICULUM 
1.3.1 ER structure and organization 
The endoplasmic reticulum (ER) is arguably the most complex, multifunctional 
organelle of eukaryotic cells. Its membrane constitutes more than the half of the total 
membrane of an average animal cell. The ER has a central role in lipid and protein 
biosynthesis. Proteins are translocated across the ER membrane, and are folded and 
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modified before they traverse the secretory pathway. It also plays a central role in other 
important processes like Ca2+ sequestration and signalling. The ER is a complex 
structure composed of membrane sheets that enclose the nucleus (the nuclear envelope) 
and an elaborate interconnected network in the cytosol (the peripheral ER). The nuclear 
ER, or nuclear envelope (NE), consists of two sheets of membranes with a lumen. The 
NE surrounds the nucleus, with the inner and outer membranes connecting only at the 
nuclear pores, and is underlain by a network of lamins. The peripheral ER is extensive 
network of cisternae and tubules and extends into the cytoplasm all the way to the 
plasma membrane. ER tubules have a very different shape from ER cisternae . ER 
tubules have high membrane curvature at their cross-section, whereas cisternae are 
comprised of extended regions of parallel, flat membrane bilayers that are stacked over 
each other with regions of membrane curvature found only at their edges. However, 
there are similarities between ER cisternae and tubules; specifically, the diameter of an 
ER tubule is similar to the thickness of an ER cistern (38 nm vs 36 nm, respectively, in 
yeast) (West et al. 2011). The lumenal space of the peripheral ER is continuous with 
that of the nuclear envelope and together they can comprise >10% of the total cell 
volume (Terasaki and Jaffe 1991). The ultrastructure of the ER has been visualized by 
electron microscopy in a number of cell types. The most obvious difference seen is 
between rough, i.e. ribosome-studded, and smooth regions of the ER (RER and SER, 
respectively). The RER often has a tubular appearance, whereas the SER is often more 
dilated and convoluted (Baumann and Walz 2001). The relative abundance of RER and 
SER found among different cell types correlates with their functions. For example, cells 
that secrete a large percentage of their synthesized proteins contain mostly RER.  
In contrast with every other organelle, the ER does not appear to undergo regulated 
fragmentation or division. Even during processes like cell division, the ER remains 
continuous. Several approaches have provided the evidence that the ER is a single 
membrane system with a continuous intralumenal space. In one experiment, a 
fluorescent dye that cannot exchange between discontinuous membranes was injected 
into cells in an oil droplet. The dye diffused throughout the cell in a membrane network 
that, based on morphological criteria, was the ER. This was observed in a number of 
different cell types including sea urchin eggs (Terasaki and Jaffe 1991) and Purkinje 
neurons (Terasaki et al. 1994). Because the dye spread in fixed as well as live cells it 
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must be diffusing through a continuous network rather than being transported by active 
trafficking. The continuity of ER membranes network was also proved by fluorescence 
loss in photobleaching (FLIP). Little is known about how the particular architecture of 
the ER is formed and maintained. It is known that the cytoskeleton is not necessary for 
the formation of a tubular network in vitro. In Xenopus egg extracts, ER networks can 
form de novo and this process is not affected by the addition of inhibitors of 
microtubule polymerization, by the depletion of tubulin from the extract or by inhibitors 
of actin polymerization (Dreier and T A Rapoport 2000). 
The atlastin proteins (and their yeast homolog Sey1) stimulates homotypic ER fusion. 
Atlastin are membrane-integral GTPase family proteins components of ER fusion 
machinery. Atlastin mutation or depletion, leads to unbranched ER tubules in 
mammalian cells (J. Hu et al. 2009) and ER fragmentation in Drosophila neurons 
whereas its overexpression leads to ER membrane expansion (Orso et al. 2009). 
1.3.2 ER dynamics  
In interphase cells, the peripheral ER is a dynamic network consisting of cisternal 
sheets, linear tubules, polygonal reticulum and three-way junctions (Allan and R D Vale 
1991). Several basic movements contribute to its dynamics: elongation and retraction of 
tubules, tubule branching, sliding of tubule junctions and the disappearance of 
polygons. These movements are constantly rearranging the ER network while 
maintaining its characteristic structure. The ER fusion machinery and the reticulon 
proteins play a stabilizing role in maintaining overall ER structure during these 
dynamics. The dynamics of the ER network depend on the cytoskeleton. In mammalian 
tissue culture cells, goldfish scale cells, and Xenopus and sea urchin embryos the ER 
tubules often co-align with microtubules. Microtubule-based ER dynamics were studied 
with time-lapse microscopy and appear to be based on two different mechanisms: via tip 
attachment complex (TAC) and ER sliding dynamics. During TAC movements, the tip 
of the ER tubule is bound to the tip of a dynamic microtubule, and the new ER tubule 
grows in a motor-independent way in concert with the dynamics of the plus-end of the 
microtubule. TAC events occur through a complex between the integral ER membrane 
protein STIM1 and a protein that localizes to the tip of a dynamic microtubule, 
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EB1,(Grigoriev et al. 2008). In ER sliding events, tubules are pulled out of the ER 
membrane by the motor proteins kinesin-1 and dynein along microtubules that are 
marked by acetylation (Friedman et al. 2010). ER sliding is the predominant mechanism 
responsible for dynamic ER rearrangements in interphase cells and is a much  is much 
more common event than tip attachments complex events (Waterman-Storer and 
Salmon 1998). The differences between TAC and ER sliding mechanisms suggest that 
they might contribute to very different ER functions. 
In yeast and plants, the actin cytoskeleton, rather than the microtubule network, is 
required for ER dynamics (W A Prinz et al. 2000). The cytoskeleton contributes to ER 
dynamics, but it is not necessary for the maintenance of the existing ER network. 
Although depolymerization of microtubules by nocodazole in mammalian tissue culture 
cells inhibits new tubule growth and causes some retraction of ER tubules from the cell 
periphery, the basic tubular-cisternal structure of the ER remains intact (Terasaki, L. B. 
Chen, and Fujiwara 1986). Similarly, actin depolymerization in yeast blocks ER 
movements but does not disrupt its structure (W A Prinz et al. 2000). 
1.3.3 Tubulation of ER membranes and cisternae shaping 
The peripheral ER in most cells contains a mixture of interconnected membrane tubules 
and cisternae Membrane tubules are a structural feature of both the ER and the Golgi 
complex (Dreier and T A Rapoport 2000; Lee, Ferguson, and L. B. Chen 1989). Both 
types of tubule have similar diameters (50–100 nm), whether formed in vitro or in vivo, 
and in the case of the ER, tubule diameter is conserved from yeast to mammalian cells, 
suggesting that their formation is a regulated and fundamental process. The relative 
amount of tubules versus cisternae depends to a large extent on the proteins that 
regulate ER membrane curvature, the reticulons and DP1/Yop1. These proteins are 
integral membrane proteins, conserved in all eukaryotes. They localize exclusively in 
the peripheral regions of the ER that presents a high membrane curvature, which 
includes the edges of cisternae as well as tubules (Hetzer, Walther, and Mattaj 2005; 
Kiseleva et al. 2007). Studies in vitro and in vivo have shown that these proteins are 
necessary for organizing the ER membrane bilayer into the shape of a tubule (J. Hu et 
al. 2008), but they also involved in membrane curvature at the edges of cisternae and 
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fenestrations (West et al. 2011). In contrast, little is known about how the ER cisternae 
get their shape. These domains are comprised of flat areas of ER membrane that are 
uniformly spaced around the ER lumen and are connected at highly curved edges. 
Partitions of Climp63, a rough-ER-specific transmembrane protein, into ER cisternae 
and its overexpression, propagates the formation of cisternal ER at the expense of 
tubules (Sparkes et al. 2010). 
Climp63 depletion do not lead to a loss of the cisternae, but alterates their intraluminal 
spacing. These data suggest that, although Climp63 is not required for cisternae 
formation, it may form intraluminal linker complexes that regulate cisternal dimensions 
(Sparkes et al. 2010). 
1.3.4 ER–organelle contacts 
The ER is not an isolated structure but it contacts almost every membrane-bound 
organelle in the cell, including mitochondria, Golgi, peroxisome, endosomes, lysosome 
and lipid droplets as well as the plasma membrane. 
1) ER–mitochondria. The ER and the mitochondria contacts sites have been studied 
both biochemically and functionally. The interface between the ER and mitochondrial 
membranes has diverse important roles in cell physiology, like lipid synthesis and Ca
2+
 
signalling, the latter of which is crucial for apoptotic regulation (De Brito and Scorrano 
2010; Csordás et al. 2006). 
2) ER–peroxisome. In both yeast and mammalian cells, peroxisomes are derived at least 
in part from the ER membrane. Some peroxisomal membrane proteins are inserted into 
the ER and trafficked to peroxisomes in vesicles. These vesicles could also provide the 
phospholipids required for the growth of peroxisomal membranes, because peroxisomes 
lack phospholipid biosynthesis enzymes (Raychaudhuri and William A Prinz 2008). 
3) ER–Golgi. Transport in the ER–Golgi is performed by COPII complex in the 
anterograde direction and by COPI in the retrograde direction. COPII vesicles are 
formed at specific sites at the endoplasmic reticulum, the so-called ER exit sites 
(ERESs), (Castillon, Shen, and Huq 2009). Electron microscopy studies have shown a 
very close contacts between the ER membrane and the trans-Golgi, which have been 
proposed to be involved in direct lipid transport  (Levine and Loewen 2006). 
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4) ER–endosome. Recent study has establish a relationship between the ER and the 
endocytic pathway. There is a direct interaction between the ER-localized phosphatase, 
PTP1B, and the endocytic cargo, EGFR, at ER–endosome contact sites, in animal cells, 
suggesting that ER proteins might modify endocytosed cargoes, (Eden et al. 2010). 
Moreover, early endosomes moves in coordination with ER dynamics, and these two 
organelles can be tightly associated over time (Friedman et al. 2010). 
5) ER–plasma membrane. The ER makes also an extensive contact with the plasma 
membrane. Studies in yeast have shown a mixture of interconnected ER tubules and 
fenestrated cisternea with the cytoplasmic surface of the plasma membrane (West et al. 
2011). This contacts are important for the regulation of phosphatidyl inositol 
metabolism, Ca
2+ 
regulation and might be sites of direct non-vesicular sterol transfer 
(De Stefani et al. 2011). 
6) ER–lipid droplets. In eukaryotes, lipid droplets may arise primarily from the ER, 
where the enzymes that synthesize neutral lipids reside (Buhman, H. C. Chen, and R V 
Farese 2001). In yeast genetically engineered to lack LDs, induction of LD formation 
has shown that they invariably arise from or close to the ER. Lipid droplets appear to 
remain in contact with the ER once formed, and there is a continuous movement of the 
proteins that associate with both compartments (Jacquier et al. 2011). 
1.4 LIPID DROPLETS 
Lipids are source of energy for the cell. They are critical determinants of membrane 
integrity, and in some cells substrates for hormones synthesis. Endogenous synthesis of 
lipid requires a significant energy consume, therefore, coordinated transports processes 
have been developed to assimilate them from the environment and store them safely. 
Lipid enter in cytoplasm as free fatty acids or as alcohols (cholesterol). Fatty acid are 
released from triacylglyercols by lipase and enter in the cell by passive diffusion, 
facilitated by fatty-acid proteins or fatty-acid translocase (Ehehalt et al. 2006). In 
contrast to fatty acids, sterols are primarily taken up into cell through endocytosis and 
lysosomal degradation of lipoproteins. A high concentration of free fatty acid is toxic to 
the cell, while alcohols, at law concentrations are bioactive as signaling molecules. 
Thus, efficient systems have evolved to limit the concentrations of acids and alcohols 
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and to retain their availability by co-esterification into neutral lipids. The majority of 
neutral lipid synthesis is completed at the endoplasmic reticulum (ER). Due to a limited 
solubility of lipids in the ER membrane bilayer and the immiscibility with the 
hydrophilic intracellular environment, the lipid are stored into cytoplasmic lipid 
droplets, a process that nullifies any impact on the osmolarity of the cytosol (Sturley and 
Hussain 2012). Lipid droplets (LDs) exist in all kind of living cells, from bacteria, to 
yeasts, plants and mammals. LDs were identified by light microscopy as cellular 
organelles in the nineteenth century. For a long time, they were largely ignored in cell 
biology research, presumably because they were perceived as immobile lipid 
accumulations with little functional relevance. Recently, they have attracted great 
interest as dynamic structures at the center of lipid and energy metabolism. Major 
findings that emphasize the diversity and dynamics of LDs are the identification of key 
proteins involved in LD biology, the interaction of LDs with other organelles and the 
different composition in lipids and proteins in different cell types and physiological 
states. Excessive lipid storage in LDs is central to the pathogenesis of several metabolic 
diseases such as obesity, diabetes and atherosclerosis, suggesting that LDs have, 
therefore a crucial role in such disorders.  
Despite the acceleration of progresses in LD research and in determining the 
associations with prominent disorders, most fundamental questions are not yet resolved. 
How are LDs formed? How proteins and lipids are recruited to LDs? How do they 
interact with other organelles? 
1.4.1 Lipid Droplets characteristics.  
A lipid droplet consists of a hydrophobic core of neutral lipids in the form of 
triacylglycerols, cholesteryl esters, or retinyl esters surrounded by a phospholipid 
monolayer. In mammalian LDs, phosphatidycholine (PC) is the main surface 
phospholipid, followed by phosphatidyethanolamine (PE) and phosphatidyinositolo 
(Bartz et al. 2007). Compared with other membranes, LDs lacks in phosphatidyserine 
and phosphatidic acid but they are enriched in lyso-PC and lyso-PE. The surface of lipid 
droplets is also decorated with proteins that provide structural and metabolic functions. 
The first lipid droplet-associated proteins identified were the perilipins and related 
 1. INTRODUCTION 
 
21 
proteins, which have important metabolic roles in the control of triacylglycerol storage 
and release from lipid droplets (D. L. Brasaemle et al. 2009). Some of the most 
frequently associated proteins are enzymes involved in triacylglycerol and phospholipid 
biosynthesis, like acyl-CoA:diacylglycerol acyltransferase 2(DGAT2), acyl-CoA 
synthetase; phosphocholine cytidylyltransferase, membrane-trafficking proteins (ARF1, 
Rab5, Rab18), and the adipose tissue triacylglycerol lipase (ATGL) (Guo et al. 2008). 
However, large scale proteomic studies have identified several other lipids droplets 
associated proteins, indicating that the protein gathering it’s a key feature for the 
function of a single LD (C. C. Wu et al. 2000).  
The mammalian adipocyte is considered the “professional” lipid droplet-storing cell, but 
lipid droplets are formed nearly by all cell types in eukaryotic organisms as well as in 
prokaryotes (D J Murphy 2001). Lipid droplets in white adipocytes are probably the 
most extensively characterized type of lipid droplet. White adipocytes contain, 
typically, a single, large lipid droplet ranging up to 100 µm in diameter, whereas in 
most other cell types, LDs, are usually less than 1 µm in size (T. Suzuki et al. 2001). 
White adipocyte lipid droplets typically occupy the majority of the cytosol, are localized 
a short distance from the plasma membrane, are associated with intermediate filaments, 
and have very limited mobility within the cell. By contrast, the multiple small lipid 
droplets present in nonadipocytes are often observed juxtaposed next to the endoplasmic 
reticulum, mitochondria, and peroxisomes. These small lipid droplets exhibit directional 
movement across long distances within the cell through interaction of lipid droplet 
associated proteins with microtubules  (Michael A Welte 2009). 
1.4.2 Lipid Droplets formation. 
Unlike most other organelles, LDs are not formed by growth and fission of existing 
droplets, but they are likely formed de novo. In bacteria, LDs are formed by lipid 
synthesis in the cell-delimiting membrane (Wältermann et al. 2005). In yeast genetically 
engineered to lack LDs, induction of LD formation shows they arise from or close to the 
ER (Jacquier et al. 2011). In eukaryotes, also, LDs may arise primarily from the ER 
(Buhman, H. C. Chen, and R V Farese 2001). Observation of a fluorescent LD protein 
and a fluorescent fatty acid show a concentration of LDs components in the ER or its 
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direct proximity within 5-15min, followed by rapid formation of lipid droplets 
(Kuerschner, Moessinger, and Thiele 2008; Turró et al. 2006). Electron microscopy 
(EM) studies have shown membrane cisternae, which could be connected to the ER, in 
close proximity to LDs (Soni et al. 2009). Despite these findings, the molecular 
mechanisms of LD formation are still not understood. How does a monolayer-coated 
LD arise from a bilayer membrane?  
Several hypothesis have been proposed for the process of LD formation. The most 
prevalent hypothesis postulates that lipids accumulate between the cytoplasmic leaflet 
of the ER membrane, and as the volume increase the leaflet swell as a globular mass 
until is pinched off from the membrane to become an independent LD (M. Suzuki et al. 
2011). An alternative model support that the LD formation occur at specialized sites of 
cytoplasmic surface of ER. These sites contain a high concentration of the LD PAT 
protein, adipophilin, that surround the forming droplets in en egg-cup-like manner in 
which LD grows through transport of neutral lipids from the ER (H. Robenek et al. 
2006). All models hypothesize that LDs are formed toward the cytosolic face of the ER 
membrane. However, cells, such as hepatocytes, also secrete neutral lipids into the ER 
lumen, indicating that LDs could be derived also from the luminal origins. Several 
problems prevent the identification of the correct model. The major reason for the 
difficulty is likely to be the small size of nascent LDs (12 nm diameter predicted), that 
is below the resolution of light microscopy. Moreover, most of the cells have LDs, 
complicating identification of nascent LDs, and there are no systems of induced LD 
formation in mammals. 
1.4.3 Lipid droplets growth. 
The size of lipid droplets varies with diameters ranging from 20-40 nm to 100 μm, 
indicating that LDs can grow in size. To accommodate more triacyglycerols, the cell 
needs to synthesize new LDs or to grow the existing one. Insertion of neutral lipids to 
existing LDs requires local synthesis or transfer from the endoplasmic reticulum. 
Phospholipids and storage lipids synthesized in the ER may be efficiently delivered to 
growing LDs through LD–ER contact sites or through increased partitioning of neutral 
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lipids into the LD subdomains or via interorganelle transport by transfer proteins 
(Moessinger et al. 2011). 
An alternative model for LD growth arises from the observations that key enzymes in 
phospholipid and neutral lipid synthesis are present on the LD surface. Thus LDs may 
acquire lipids through local synthesis. Several studies have demonstrate the implication 
o f a number of proteins and lipid factors involved in the growth of lipid size  
Cell death-inducing DFF45-like effector (CIDE) family proteins, including Cidea, 
Cideb, and Fsp27 (fat-specific protein of 27 kDa), are LD-associated proteins that have 
recently emerged as regulators of lipid storage and energy homeostasis (J. Gong, Sun, 
and P. Li 2009). Fsp27-deficient white adipocytes lose unilocular LDs, and accumulate 
many small LDs (Nishino et al. 2008). While the ectopic expression of Cidea or Fsp27 
enhances the size and reduces the number of LDs. Furthermore, hepatic Cidea 
expression is upregulated by saturated fatty acids and plays a crucial role in fatty acid-
induced hepatic steatosis in mice and humans (Zhou et al. 2012). Perilipin1 is one of the 
most widely characterized proteins of the LD surface. Perilipin1 is the founding 
member of the PAT (perilipin, adipophilin and TIP47) family of LD-coating proteins 
that regulates lipolysis in adipocyte. Perilipin1 deficient mice exhibit dramatically 
reduced adipocyte and LD size, suggesting that perilipin1 may induce the formation of 
giant lipid droplets (Martinez-Botas et al. 2000). 
Triacyglycerols (TAG) and sterols (SE) and not other lipids are important not only for 
the biogenesis of LDs, as demonstrated by the existence of a LD free yeast strain, where 
the synthesis of TAG and SE is abolished owing to the absence of diacylglycerol 
(DAG) and sterol acyltransferases, but they are also important for their growth of size 
(Oelkers et al. 2002). The composition of the phospholipid monolayer coating LD 
surface may vary from organism to organism, but phosphotidylcholine (PC) and 
phosphotidylethanolamine (PE) are the major components of most LDs (Bartz et al. 
2007). During LD expansion in Drosophila S2 and mammalian cells, phosphocholine 
cytidyltransferase, enzyme of PC synthesis is targeted to the LD surface and activated, 
thereby providing enough PC to meet the needs of LD growth and proliferation. PC is a 
cylindrical lipid that has the unique ability to stabilize LDs and prevent LD coalescence. 
Indeed, when PC synthesis is compromised, giant LDs are readily formed in S2 cells 
(Krahmer et al. 2011). 
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Two independent screens of the yeast deletion library have found ‘supersized’ LDs in 
cells deleted for FLD1. The mammalian orthologue of Fld1p is seipin, mutant forms of 
which have been linked to Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2), 
a recessive disorder characterized by an almost complete loss of adipose tissue, severe 
insulin resistance and fatty liver. Moreover giant LDs have been found in the salivary 
glands of seipin deficient Drosophila (Tian et al. 2011). These results establish seipin as 
an important factor in regulating LD dynamics, particularly size and distribution.  
An additional model proposed for the growth of LDs is the fusion between the existing 
LDs. LD fusion has been proven to be a rare event under normal conditions, recently 
has been observed in mutant cells, as well as in 3T3 L1 adipocytes upon insulin and 
fatty acid treatment. 
SNARE proteins (soluble N-ethylmaleimide-sensitive factor attachment receptor 
proteins) that mediate homotypic fusion of bilayer-bound vesicles during cellular 
trafficking, have been recently considered as possible candidates of LD fusion. 
Knockdown of genes SNAP23, syntaxin-5 and VAMP4 in NIH 3T3 cells decrease the 
rate of LD fusion (Boström et al. 2007). However it is unclear how SNARE proteins 
would mediate fusion of monolayer-bound vesicles. Other recent studies have identified 
additional proteins that influence LD size, but the role of these proteins in LD biology 
requires further analyses 
Furthermore, LD fusion can be induced by pharmacological agents like propranolol and 
other drugs, which may trigger fusion by inserting into and disrupting LD surface 
monolayer (S. Murphy, Martin, and Parton 2010). 
1.4.4 Lipid droplets motility  
LDs in non adipocyte cells are capable of rapid, microtubule-dependent movement as 
shown with live-cell imaging of the Drosophila embryos (M A Welte et al. 1998) and 
mammalian HuH-7 cells (Targett-Adams et al. 2003). The directional movement is 
driven by minus-end and plus-end motors, dynein and kinesin-1 respectively (S P Gross 
et al. 2000). LDs move directionally in axons of Aplysia by uncharacterized 
mechanisms (Savage, D. J. Goldberg, and Schacher 1987). In Drosophila, LSD2, a 
homolog of mammalian perilipin, was shown to regulate LD movement by coordinating 
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the motors with opposite polarites. Antibodies neutralizing dynein reduce lipid droplet 
formation and depolymerization of microtubules with nocodazole and inhibits 
homotypic fusion of lipid droplets (Andersson et al. 2006). Despite the microtubule 
association, LDs appear to distribute randomly in cultured cells, and patterns suggesting 
cytoskeletal engagement, such as linear alignment and/or centripetal concentration are 
not usually seen. This result suggests that LD distribution is not controlled only by 
microtubules, but is regulated by many factors including association with other 
organelles (M. Suzuki et al. 2011). These organelle associations might facilitate the 
exchange of lipids, either for anabolic growth of LDs or for their catabolic breakdown. 
Instead, LDs might provide a means of transporting lipids between organelles in the 
cell.  
1.4.5 Lipid droplets protein 
Like any other organelle, the LD surface monolayer contains a characteristic set of 
proteins. Mass spectrometry analysis of LD from various cell lines and tissues, has 
identified two groups of proteins that dominate. The first group is the PAT family, with 
structural and regulatory function on LD formation (D. L. Brasaemle 2007). The second 
group consists of enzymes of lipid metabolism that acts on triglyceride and enzymes of 
sterol biogenesis. From a structural point of view the LD proteome  consists of three 
classes, peripherally associated proteins (like PAT family), lipid anchored proteins of  a 
small GTPase type, and monotopic integral membrane proteins. The monotopic 
membrane proteins share a typical organization, characterized by a long hydrophobic 
region that typically extends to 30-40 amminoacids, with flexible regions with many 
residues that destabilize a regular straight alpha helix (Ostermeyer et al. 2004). The LDs 
are closely associated with other organelles, in particularly with the ER, thus can 
confuse the proteomic analysis. For such reasons its often unclear to distinguish 
between genuine LD protein and other proteins. Moreover, it can be more confusing, 
because some LD proteins have other well known functions. Histones were 
unpredictably found by LD proteomics to target LDs in Drosphila embryos (Cermelli et 
al. 2006). Thus LDs may transiently store other proteins that otherwise might aggregate, 
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like α-synuclein, a Parkinson’s disease associated protein prone to self aggregation, 
localize to LDs (Cole et al. 2002).  
1.4.6 Lipid droplets in mammalian physiology and disease 
Besides storing lipids, different studies suggest that lipid droplets have other functions 
in cellular  physiology and pathology. LDs are a source of substrates for steroid 
hormone synthesis, and contain the majority of the body's vitamin A and it's metabolites 
(Blaner et al. 2009) in retinoid stellate cells in the liver. In hepatocytes, LDs store 
triacylglycerol and cholesteryl esters that provide up to 70% of the substrate for the 
assembly of very low-density lipoproteins (Lehner et al., 2009). Moreover, they appear 
to have important functions in several cell types of the immune system, like 
macrophages and leukocytes by participating in inflammation and the immune response 
(Melo et al. 2011). In cardiomyocyte, triacylglyclerol of LDs are hydrolyzed to generate 
lipid ligands that activate the nuclear receptor peroxisome proliferator-activated 
receptor α and mitochondrial function. Therefore, suggesting that lipids of LDs might 
act as signaling molecules or ligand for the transcription factors (Haemmerle et al. 
2002). Lipid droplet can serve as temporary storage site for hydrophobic proteins to 
prevent their degradation or/and they aggregation. One example is the accumulation of 
protein α-synuclein, dysfunction of which is associated with Parkinson’s disease (Cole 
et al. 2002). 
An excessive or defective storage of lipid in LDs can lead to many metabolic diseases, 
or diabetes and atherosclerosis. Accumulation of triacylglyclerol in LDs in liver and 
pancreatic β-cells and skeletal muscule can lead to lipotoxicity and determine insulin 
resistance, obesity and nonalcoholic steatohepatits (Lusis et al., 2010). Macrophage 
excessive storage of lipid in LDs is a characteristic of foam cell formation in 
atherosclerosis. Dysfunction of LDs hydrolysis is associated with accumulation of lipids 
in skeletal and cardiac muscle. Mutations in adipose triglyceride lipase (ATGL) cause 
myopathy, whereas mutations in the activator of ATGL (CGI-58) cause Chanarin –
Dorfman syndrome, that present the same symptoms caused by ATGL deficiency 
(Fischer et al. 2007; Schweiger et al. 2009).  
 1. INTRODUCTION 
 
27 
Lipid droplets play an important role in the pathogenesis of bacteria and virus. The viral 
genome of hepatitis C virus, after replication, is recruited to the ER surrounding lipid 
droplets and is encapsulated by the viral nucleocapisd core to produce progeny virions.  
Recent studies have shown also a correlation between cancer and LDs. In most cancer 
cells there is an upregulation of synthesis of fatty acid, presumably to provide the lipid 
necessary for the membrane proliferation. Some of this cells present large LDs (Patricia 
T Bozza and Viola n.d.). However the mechanism for the LD accumulation in cancer 
cells is unclear.  
1.5 DROSOPHILA IN THE STUDY OF NEURODEGENERATIVE 
DISEASES 
A growing number of neurodegenerative diseases, as well as other human diseases, are 
being modelled in Drosophila. 
Drosophila is used as a platform to identify and validate cellular pathways that 
contribute to neurodegeneration and to identify promising therapeutic targets by using a 
variety of approaches from screens to target validation. The unique properties and tools 
available in the Drosophila system, coupled with the fact that testing in vivo has proven 
highly productive, have accelerated the progress of testing therapeutic strategies in mice 
and, ultimately, humans. 
1.5.1 How fly models can complement other systems 
In studying human neurodegenerative diseases, one typically employs multiple systems, 
including cell-based models in which one can generate stably expressing lines and 
phenocopy cellular aspects of disease. However, in many cases, the response of the 
intact organism is not fully recapitulated in cell lines. In vitro, intersecting physiological 
pathways and responses (e.g., neurotransmitter circuitry and interactions with support 
cells, etc.) are eliminated, nonautonomous cellular influences are removed, and new 
parameters such as those used to immortalize cells, are often introduced, thus reducing 
the ability of cultured cells to mirror in vivo pathology. It can also be very difficult to 
obtain a functional measure of the impact of pathogenic proteins in in vitro systems. 
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In contrast, although mice and other mammalian model systems offer in vivo 
opportunities and extensive similarity to the human brain, the length of time and cost 
required to perform experiments comparable to those possible in flies can be 
prohibitive. 
Flies, on the other hand, are a minuscule system model with a rapid generation time, 
inexpensive culture requirements, large progeny numbers produced in a single cross and 
a small highly annotated genome devoid of genetic redundancy. Flies allow excellent 
genetic manipulation and the pathways are considered generally highly conserved with 
vertebrates.  
A comparative genome analysis reveals that approximately 75% of all human disease 
genes have a Drosophila ortholog (Fortini et al. 2000; Reiter et al. 2001). Drosophila 
has homologues of genes that, when disrupted, cause a broad spectrum of human 
diseases such as neurological disorders, cancer, developmental disorders, metabolic and 
storage disorders and cardiovascular disease, as well as homologues of genes required 
for the visual, auditory and immune systems. This and other bioinformatic analyses 
indicate that Drosophila can serve as a complex multicellular assay system for 
analysing the function of a wide array of gene functions involved in human diseases . 
The anatomy and development of Drosophila nervous system has been extensively 
characterized and many tools are available to identify specific neuronal subtypes. 
Neuronal functions (i.e. synaptic transmission) and survival can been measured in flies, 
as can learning and memory. 
Drosophila has been used to model neurodegenerative diseases ranging from tauopathy, 
Alzheimer's disease (AD), and Parkinson's disease (PD) to fragile X syndrome as well 
as several polyglutamine–repeat diseases such as Spinocerabellar ataxia and 
Huntington's disease (Marsh and Thompson 2004; Muqit and Feany 2002). 
1.5.2 Diseases can be modelled in flies 
There are three main approaches to modelling human diseases, including 
neurodegenerative disorders, in Drosophila. 
Traditionally, forward-genetic approaches have been used. Mutations are selected on 
the basis of a neurodegenerative phenotype, and human homologues of the identified 
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Drosophila gene products are plausible candidates for involvement in 
neurodegenerative diseases. Alternatively, 'reverse genetics' can be used. In this case, 
the Drosophila homologue of a specific gene that is implicated in a human disease is 
targeted, and phenotypes that result from altered expression of the gene are studied. 
Useful phenotypes can emerge by reducing or eliminating (knocking out) gene 
expression, or by overexpressing the gene product. 
An even more direct path from human disease to invertebrate model is possible with 
certain human disorders: those caused by a toxic dominant gain-of-function mechanism. 
If disease is produced in humans by the action of a toxic protein, it might not be 
necessary, or even desirable, to manipulate the invertebrate homologue of the human 
disease-related gene. Instead, simple expression of the toxic human protein in the model 
organism might accurately model the disease. Toxic dominant mechanisms almost 
certainly operate in neurodegenerative disorders such as Huntington's disease and 
amyotrophic lateral sclerosis (ALS). 
Nearly all of the current fly models of neurodegenerative diseases have been made 
using the GAL4/UAS (upstream activating sequence) system which allows the ectopic 
expression of a transgene in a specific tissue or cell type (Brand and Perrimon 1993). 
In this system, a human disease-related transgene is placed under the control of the 
yeast transcriptional activator GAL4. In the absence of GAL4, the transgene is inactive. 
When flies that carry the human disease-related transgene are crossed to flies that 
express GAL4 in a specific tissue or cell type, the transgenic protein is made only in the 
tissues that have GAL4 (Figure 2).  
Many cell-type and developmentally regulated GAL4 ('driver') lines exist at present, 
and are readily available from public stock centres. So, the effect of expressing a human 
disease-related transgene in many different tissues and at various developmental times 
can be assayed without creating many independent transgenic fly strains. This system 
provides a particular advantage for studying neurodegenerative disease, because the 
issue of cell-type specificity can be readily addressed.  
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Figure 2. GAL4/UAS (upstream activating sequence) system allows the ectopic expression of a 
human transgene in a specific tissue or cell type. 
 
Once relevant Drosophila models of neurodegenerative disease have been created, the 
genetic potential of the system can be exploited. Second-site modifier analysis identifies 
unlinked mutations that either suppress or enhance neurodegeneration. Such modifier 
genes encode proteins that are involved in the pathogenesis of the neurodegenerative 
process in flies, and potentially in the human disease as well. One strength of genetic 
analysis in Drosophila is that the whole cellular cascade that mediates 
neurodegeneration, including both specific interactors and downstream elements, can be 
defined. In practical terms, the phenotype that is used to select genetic modifiers should 
be externally visible, easily scored and involve structures that are not essential for 
viability. Abnormalities of the Drosophila eye have therefore been the phenotypes of 
choice in modifier screens. 
Modifier identification can follow both biased and non-biased strategies. In the biased 
'candidate' approach, mutations are selected on the basis of pre-existing hypotheses, and 
these mutations are tested for their ability to suppress or enhance neurodegeneration. 
Candidate testing can rapidly confirm the role of suspected mediators, but is limited by 
preformed hypotheses. The second approach is to do an unbiased forward-genetic 
screen. A forward-genetic screen interrogates the genome for mutations that modify a 
neurodegenerative phenotype, without bias as to possible function. Random mutations 
are produced by chemical or insertional mutagenesis, and the ability of these mutations 
to suppress or enhance the phenotype of interest is tested. The unbiased approach has 
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the potential to identify new proteins, or to implicate previously defined cellular 
pathways that were not suspected to be important in neurodegenerative disease (Muqit 
and Feany 2002). 
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2. AIMS 
Hereditary Spastic Paraplegia (HSP) is a complex and heterogeneous group of genetic 
disorders clinically characterized by progressive spasticity and weakness of lower 
limbs. To date over 54 loci have been recognized but only 27 genes have been 
molecularly characterized. The genetic complexity of the disease and the lack of 
information concerning the pathways of most of the genes involved, prevent the 
development of valid therapeutic approaches. Mutations of the SPG31 gene, which 
encodes for REEP1 protein, are responsible for autosomal dominant form of HSP. 
Recently, in vitro experiments conducted in mammalian cell systems have shown that 
REEP1 interacts with other two HSP related genes, Spastin and Atlastin-1, within the 
tubular ER membrane to coordinate ER shaping and microtubule dynamics. However, 
the exact function of REEP1 and the mechanism which lead to axonophaty in HSP 
remain to date unresolved.  
The aim of this project was to try to understand the biological role of REEP1 by in vivo 
analysis of loss and gain of function transgenic lines of the Drosophila homologue D-
REEP1. This approach is based on the high degree of evolutionary conservation of 
genes structure and function between Drosophila and human. The analysis of the 
cellular phenotype generated by down regulation and over-expression of REEP1 
through biochemical, molecular and Confocal imaging techniques have represented the 
strategy for the aim of this thesis.  
Moreover, we wanted to evaluate the in vivo effects produced by pathological form of 
D-REEP1 protein. To gain insight into the pathological mechanism underlying HSP 
neurodegeneration we generated transgenic animals expressing D-REEP1 protein with 
missense mutation. 
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3. METHODS 
3.1 MOLECULAR BIOLOGY TECHNIQUES: GENERATION OF 
CONSTRUCTS 
The H-REEP1 cDNA was previously obtained from HeLa cells RNA extract followed 
by RT reaction and cloned in the pcDNA3.1/Zeo(+) cloning vector (Qiagen). 
The D-REEP1 cDNA was obtained from Drosophila RNA extract and cloned in the 
pDrive cloning vector (Qiagen): D-REEP1/pDrive.  
3.1.1 Amplification of H-REEP1 and D-REEP1 cDNA 
Full-length H-REEP1 cDNA (606 pb) D-REEP1 cDNA (867 pb) were obtained by RT-
PCR from, respectively, HeLa cells total RNA extract and Drosophila total RNA. 
RT-PCR is short for Reverse Transcription-Polymerase Chain Reaction. RT-PCR, is a 
technique in which a RNA strand is “reverse” transcribed into its DNA complement, 
followed by amplification of the resulting DNA using a polymerase chain reaction 
(PCR). 
Transcribing a RNA strand into its DNA complement is termed reverse transcription 
(RT), and is accomplished through the use of a RNA-dependent DNA polymerase 
(reverse transcriptase). Afterwards, a second strand of DNA is synthesized through the 
use of a deoxyoligonucleotide primer and a DNA-dependent DNA polymerase. The 
complementary DNA and its anti-sense counterpart are then exponentially amplified via 
a polymerase chain reaction (PCR). The original RNA template is degraded by RNase 
H treatment. 
3.2 RT-PCR 
The complementary strand from RNA template was obtained using the ThermoScript 
TM 
RNase H
-
 Reverse Transcriptase (Invitrogen); for PCR reaction we used Phusion High-
Fidelity DNA polymerase (Finnzymes). The entire procedure is described below. 
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The misture was incubated at 65°C for 5 minutes and then placed on ice. The contents 
of the tube was collected by brief centrifugation and to the tube were added: 
Component Volume/ 20 ul reaction 
RTBuffer (5X) 4 ul 
DTT 0.1M 1 ul 
primer Oligo(dT) 1 ul 
RNaseOUTTM 1 μl 
Superscript III (retrotrascriptase) 200U 
Contents of the tube were mixed gently and incubated at 50°C for 60 minutes. The 
reaction was terminated by heating at 75°C for 5 minutes. To remove the original RNA 
template, 1μl (2 units) of E. coli RNase H was added and incubated at 37°C for 20 
minutes. 
3.2.1 Cloning of the H-REEP1 cDNA fragment in pcDNA3.1/Zeo(+) 
plasmid: H-REEP1-HA/pcDNA3.1/Zeo(+), H-REEP1-Myc/ 
pcDNA3.1/Zeo(+) and HA/H-REEP1-Myc/ pcDNA3.1/Zeo(+) 
pcDNA3.1/Zeo(+) is a plasmid designed for high level expression in a variety of 
mammalian cell lines (see Appendix C). Three differently tagged REEP1 forms were 
cloned in the pcDNA3.1/Zeo(+) plasmid: REEP1-HA, REEP1-Myc and HA-REEP1-
Myc. 
To insert the HA epitope in the N-terminus of REEP1, cDNA was amplified from total 
extract using the following primers: 
Component Volume/ 12 ul reaction 
Oligo(dT)20 (50μM) 1 ul 
Total RNA 1 ug 
10mM dNTP mix (10 mM each dATP, dGTP, 
dCTP and dTTP at neutral pH) 
1 ul 
H2O add to 12 ul 
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Forward  
FHAREEP1EcorI 5’GAATTCATGTACCCATACGATGTTCCTGACTA 
TGCGGGCGTGTCATGGATCATCTCCAGGC3’ 
Reverse  
RREEP1XhoIStop 5’CTCGAGCTAGGCGGTGCCTGAGCTGCTAGCG 
CT3’ 
 
To insert the Myc epitope in the C-terminus of H-REEP1, cDNA was amplified using 
the following primers: 
Forward  
FREEP1EcorI 5’GAATTCATGGTGTCATGGATCATCTCCAGGC3’ 
Reverse  
RREEP11XhoIMyc 
 
5’CTCGAGTTACAGATCTTCTTCAGAAATAAGTTT
TTGTTCGGCGGTGCCTGAGCTGCTAGCGCT3’ 
To insert the HA epitope in the N-terminal and Myc epitope in the C-terminal of 
REEP1, cDNA was amplified using the following primers: 
Forward  
FHAREEP1EcorI 
 
5’GAATTCATGTACCCATACGATGTTCCTGACTAT
GCGGGCGTGTCATGGATCATCTCCAGGC3’ 
Reverse  
RREEP1XhoIMyc 
 
5’CTCGAGTTACAGATCTTCTTCAGAAATAAGTTT
TTGTTCGGCGGTGCCTGAGCTGCTAGCGCT3’ 
3.2.2 Cloning of the D-REEP1 cDNA fragment in pcDNA3.1/Zeo(+) 
plasmid: D-REEP1-HA/pcDNA3.1/Zeo(+), D-REEP1-Myc/ 
pcDNA3.1/Zeo(+) and HA-D-REEP1-Myc/ pcDNA3.1/Zeo(+) 
To insert the HA epitope in the N-terminus of D-REEP1, cDNA was amplified from 
total RNA extract using the following primers: 
Forward  
FHAEcoRI D-REEP1 GAATTCATGTACCCATACGATGTTCCTGACTAT 
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GCGGGCATCAGCAGCCTGTTTTC 
Reverse 
RXbaI D-REEP1 stop 
 
TCTAGATTAGTAGTTTTCCACATCCACATC 
To insert the Myc epitope in the C-terminus of D-REEP1, cDNA was amplified using 
the following primers: 
Forward  
FNotI D-REEP1 GCGGCCGCATGATCAGCAGCCTGTTTTC 
Reverse 
RXbaI D-REEP1myc 
 
TCTAGATTACAGATCTTCTTCAGAAATAAGTTT 
TTGTTCGTAGTTTTCCACATCCACATC 
 
To insert both epitopes, HA at N-terminus and c-myc at C-terminus, in D-REEP1, 
cDNA was amplified using the following primers: 
Forward  
FHA EcoRI D-REEP1 GAATTCATGTACCCATACGATGTTCCTGACTA 
TGCGGGCATCAGCAGCCTGTTTTC 
Reverse 
RXbaI D-REEP1myc 
 
 
TCTAGATTACAGATCTTCTTCAGAAATAAGTT 
TTTGTTCGTAGTTTTCCACATCCACATC 
 
To generate each of these constructs the protocol used was the following: 
PCR 
Component Volume/ 50 ul reaction 
H-REEP1/D-REEP1cDNA (20 μg/ul) 1 ul 
Buffer 10X 2 ul 
MgCl2 (50mM) 2 μl 
dNTPs (10 mM) 0.5 ul 
Forward (10 uM) 1 ul 
Reverse (10 uM) 1 ul 
Taq DNA polymerase (2 U/μl) 0.4 ul 
H2O add to 50 ul 
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PCR cycle 
Cycle step Temperature Time 
Initial denaturation 94°C 5 minutes 
Denaturation 94°C 30 seconds 
Annealing 58°C 30 seconds 
Extension 72°C 1 minute 
Final extension 72°C 10 minutes 
Restriction reactions 
pcDNA3.1/Zeo(+) plasmid, D-REEP1and H-REEP1 PCR fragments, containing HA 
and/or c-myc epitops, were digested with restriction enzymes in the following reactions: 
Component Volume/ 
50 ul reaction 
Component Volume/ 
50 ul reaction 
H-REEP1 PCR fragment 
(50ng/ul) 
20 ul pcDNA3.1/Zeo(+) plasmid 
(100ng/ l) 
5 ul 
EcoRI (10U/ul) 2 ul EcoRI (10U/ul) 2 ul 
XhoI (10U/ul) 2 ul XhoI (10U/ul) 2 ul 
10X L buffer 5 ul 10X L buffer 5 ul 
H2O to 50 ul H2O to 50 ul 
 
D-REEP1 PCR fragment 
(50ng/ul) 
  
pcDNA3.1/Zeo(+) plasmid 
 
 
EcoRI (10U/ul) 2 ul EcoRI (10U/ul) 2 ul 
XBaI (10U/ul) 2 ul XBaI (10U/ul) 2 ul 
10X L buffer 5 ul 10X L buffer 5 ul 
H2O to 50 ul H2O to 50 ul 
 
Mixed products were incubated at 37°C for 1 hour and successively separated by 
electrophoresis through a 1% agarose gel. The bands corresponding to the H-REEP1 
PCR fragment and pcDNA3.1/Zeo(+) plasmid were cut from gel and purified using the 
33 cycles 
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QIAquick Gel Extraction Kit Qiagen). Purified DNA products were eluted in 10 μl of 
elution buffer.  
The purified DNA fragments were ligated as follows: 
Ligation 
Component Volume/ 10 ul reaction 
Purified pcDNA3.1/Zeo(+) plasmid 
(100ng/ul) 
3 ul 
Purified H-REEP1 fragment (50 ng/ul) 6 ul 
5X Buffer 3 ul 
T4 DNA ligase (1U/ ul) Invitrogen 2 ul 
H2O to 20 ul 
The mixture was incubated at 16°C for 1 hour. 
Transformation 
Ligation mixture was used for transformation of chemically competent DH5alpha cells 
(Invitogen). Transformed bacteria were plated on LB–ampicillin agar plates and 
incubated overnight at 37°C. 10 colonies for each construct were grown in LB medium 
with ampicillin. Plasmid DNA was successively purified by minipreparation protocol 
and tested by restriction analysis for the right insertion. 
Purification of H-REEP1 and D-REEP1 plasmids 
Plasmid DNA were purified from an overnight culture using a “Midi” plasmid 
purification kit, according to Qiagen Plasmid Midi purification protocols. The final 
pellets were re-suspended in 50 ul of TE buffer. 
3.2.3 Cloning of the H-REEP1 and D-REEP1 cDNA fragment in 
pcDNA3.1/Zeo(+) with GFP at N-terminus  
To insert GFP sequence at N-terminus of H-REEP1 and D-REEP1, the GFP sequence 
was amplified from pEGFP-N1 vector using the following primers: 
 3. METHODS 
 
41 
F GFPXhoI  CTCGAGGGTACCATGATCAGCAGCCTGTTTTC 
R GFPEcoRI   GAATCCTCTAGAGTAGTTTTCCACATCCACATC 
After blunt-end ligation GFP sequence was cloned in pBLUESCRIPT II KS/SK (+).  
pBLUESCRIPT II KS/SK (+) plasmid (Appendix C) and GFP sequence were digested 
with restriction enzymes in the following reactions:  
Component Volume/ 
50 ul reaction 
Component Volume/ 
50 ul reaction 
GFP sequence (50ng/ul) 20 ul pBLUESCRIPT II KS/SK 
(+) (100ng/ l) 
5 ul 
EcoRI (10U/ul) 2 ul EcoRI (10U/ul) 2 ul 
XhoI (10U/ul) 2 ul XhoI (10U/ul) 2 ul 
10X L buffer 5 ul 10X L buffer 5 ul 
Add H2O to 50 ul  Add H2O to 50 ul  
Mixed products were incubated at 37°C for 1 hour and successively separated by 
electrophoresis through a 1% agarose gel. The bands corresponding to the GFP 
sequence and pBLUESCRIPT II KS/SK (+) plasmid were cut from gel and purified 
using the QIAquick Gel Extraction Kit (Qiagen). Purified DNA products were eluted in 
10 μl of elution buffer.  
The two purified DNA fragments were ligated as follows: 
Component Volume/ 10 ul reaction 
Purified pBLUESCRIPT II KS/SK (+) plasmid 
(100ng/ul) 
1 ul 
Purified GFP fragment (50 ng/ul) 4 ul 
10X Ligation buffer 1 ul 
Ligase enzyme (Invitrogen) 2 ul 
H2O to 10 ul 
The mixture was incubated at 16°C for 1 hour. 
pcDNA3.1/Zeo(+) plasmid was digested with XhoI and XbaI restriction enzymes, GFP 
sequence was digested with EcoRI and XhoI restriction enzyme and H-REEP1 and D-
REEP1 cDNA were digested with EcoRI and XbaI restriction enzyme. The bands 
corresponding to each of this sequence  were cut from gel and purified using the 
QIAquick Gel Extraction Kit (Qiagen) and eluted in 10 μl of elution buffer. The 
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purified DNA fragments were ligated as described above. Ligation mixture was used for 
transformation of chemically competent DH5 alpha cells (Invitogen). Transformed 
bacteria were plated on LB–ampicillin agar plates and incubated overnight at 37°C.  
3.2.4 Site specific mutagenesis  
To introduce specific nucleotide substitutions in REEP1 cDNA, site-directed 
mutagenesis was performed using Pfu Ultra HF DNA polymerase (Startagene).  
The basic procedure utilizes a supercoiled double-stranded DNA (dsDNA) vector with 
an insert of interest and two synthetic oligonucleotide primers containing the desired 
mutation. The oligonucleotide primers, each complementary to opposite strands of the 
vector, are extended during temperature cycling by the Pfu Ultra DNA polymerase 
polymerase. Pfu Ultra DNA polymerase replicates both plasmid strands with high 
fidelity and without displacing the mutant oligonucleotide primers. Incorporation of the 
oligonucleotide primers generates a mutated plasmid containing staggered nicks. 
Following temperature cycling, the product is treated with DpnI. The DpnI 
endonuclease (target sequence: 5´-Gm6ATC-3´) is specific for methylated and 
hemimethylated DNA and is used to digest the parental DNA template and to select for 
mutation-containing synthesized DNA. DNA isolated from almost all E. coli strains is 
dam methylated and therefore susceptible to DpnI digestion. The nicked vector DNA 
containing the desired mutations is then transformed into XL1-Blue chemiocompetent 
cells.  
PCR reaction 
Component Volume/ 50 ul reaction 
H-REEP1-HA/pcDNA3.1/Zeo(+) (50 ng/ul) or 
H-REEP1-Myc/pcDNA3.1/Zeo(+) (50 ng/ul) 
1 ul 
Forward (10 uM) 1 ul 
Reverse (10 uM) 1 ul 
10 mM dNTPs  1 ul 
10X PfuUltra HF reaction buffer 5 ul 
Pfu Ultra HF DNA polymerase (2.5 U/ ul) 1 ul 
H2O to 50 ul 
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HD-REEP1-HA/pcDNA3.1/Zeo(+) (50 ng/ul) or 
HD-REEP1-Myc/pcDNA3.1/Zeo(+) (50 ng/ul) 
1 ul 
Forward (10 uM) 1 ul 
Reverse (10 uM) 1 ul 
10 mM dNTPs  1 ul 
10X PfuUltra HF reaction buffer 5 ul 
Pfu Ultra HF DNA polymerase (2.5 U/ ul) 1 ul 
H2O to 50 ul 
  
PCR cycle 
Cycle step Temperature Time 
Initial denaturation 95°C 1 minute 
Denaturation 95°C 50 seconds 
Annealing 52°C 50 seconds 
Extension 68°C 10 minutes 
Final extension 68°C 30 minutes 
Following temperature cycling, the reaction was placed on ice for 2 minutes.   
1 μl of the DpnI restriction enzyme (10 U/μl) was added directly to the amplification. 
The reaction was mixed by pipetting the solution up and down several times, and 
immediately incubated at 37°C for 1 hour to digest the parental (i.e., the non mutated) 
supercoiled dsDNA. 
Specific primers used for single and multiple substitutions 
Aminoacidic 
Substitutions 
 Primers for H-REEP1 cDNA 
In small letters are indicated the substituted 
nucleotides                                                                                                                                                                                                                                                                                                                      
   
P19R Forward 5’TATTTGGCACCCTTTACCGTGCGTATTA
TTCCTAC3’ 
 Reverse 5’GTAGGAATAATACGCACGGTAAAGGGT
GCCAAATA3’ 
   
18 cycles 
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A20E Forward 5’TGGCACCCTTTACCCTGAGTATTATTCC
TACAAG3’ 
 Reverse 5’CTTGTAGGAATAATACTCAGGGTAAAG
GGTGCCA3’ 
   
A132V Forward 5’TTGAACGTGGCCGTCACAGCGGCTGTGA
TG3’ 
 Reverse 5’CATCACAGCCGCTGTGACGGCCACGTTC
AA3’ 
   
D56N Forward 5’ GAGACATTCACAAACATCTTCCTTTG 3’ 
 Reverse 5’ CAAAGGAAGATGTTTGTGAATGTCTC 3’ 
 
Aminoacidic 
Substitutions 
  
Primers for D-REEP1 cDNA 
 
P19R Forward 5’TGCGGCACCCTGTACCGGGCATATGCCT
CATAC 3’ 
 Reverse 5’GTATGAGGCATATGCCCGGTACAGGGT
GCCGCA3’ 
   
A20E Forward 5’GGCACCCTGTACCGGGAATATGCCTCAT
ACTCC3’ 
 Reverse 5’GGAGTATGAGGCATATTCCCGGTACAG
GGTGCCGCA 3’ 
Transformation 
10 μl of each reaction mixture was used for transformation of chemically competent 
XL1-blue bacteria. Transformed bacteria were plated on LB–ampicillin agar plates and 
incubated overnight at 37°C.  
10 colonies were grown in LB medium with ampicillin. Plasmid DNA was successively 
purified by minipreparation protocol (see Appendix A for procedure). 
Plasmid purification  
Plasmids were purified from an overnight culture using a “Midi” plasmid purification 
kit, according to Qiagen Plasmid Midi purification protocols. The final pellets were re-
suspended in 50 ul of TE buffer. 
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Sequencing of mutated REEP1 cDNA  
Two clones of each construct have been sequenced to verify the presence of the specific 
mutations. The DNA clones were sequenced by Bio-Fab Research 
(http://www.biofabresearch.it/index2.html) using the following primers:  
T3 universal primer 5’AGCACCTGCAGCTCTTCACT3’ 
  
T7 universal primer 5’TAATACGACTCACTATAGGG3’ 
  
3.2.5 Cloning the D-REEP1 wt cDNA, and P19R D-REEP1 cDNA in 
pUAST plasmid 
pUAST plasmid (Appendix C), D-REEP1 wt cDNA and D-REEP1 cDNA carrying the 
P19R mutation in pcDNA3.1/Zeo(+) were digested with EcoRI and XbaI restriction 
enzymes in the following reactions:  
Component Volume/ 
50 ul reaction 
Component Volume/ 
50 ul reaction 
D-REEP1cDNA/ 
pcDNA3.1/Zeo(+) 
(50ng/ul) 
20 ul pUAST plasmid (100ng/ l) 5 ul 
EcoRI (10U/ul) 2 ul EcoRI (10U/ul) 2 ul 
XbaI (10U/ul) 2 ul XhoI (10U/ul) 2 ul 
10X L buffer 5 ul 10X L buffer 5 ul 
H2O to 50 ul  H2O to 50 ul  
Mixed products were incubated at 37°C for 1 hour and successively separated by 
electrophoresis through a 1% agarose gel. The bands corresponding to the D-REEP1 
cDNA and pUAST plasmid were cut from gel and purified using the QIAquick Gel 
Extraction Kit (Qiagen). Purified DNA products were eluted in 10 μl of elution buffer.  
The two purified DNA fragments were ligated as follows: 
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Component Volume/ 10 ul reaction 
Purified pUAST plasmid (100ng/ul) 1 ul 
PurifiedD-REEP1 cDNA fragment (50 ng/ul) 4 ul 
10X Ligation buffer 1 ul 
Ligase enzyme (Invitrogen) 2 ul 
H2O to 10 ul 
The mixture was incubated at 16°C for 1 hour. 
 
3.2.6 Cloning the H-REEP1 wt cDNA, A132V H-REEP1 cDNA and 
P19R H-REEP1 cDNA in pUAST plasmid 
pUAST plasmid (Appendix C), H-REEP1 wt cDNA and H-REEP1 cDNA carrying 
P19R and A132V mutations, in pcDNA3.1/Zeo(+) were digested with EcoRI and XhoI 
restriction enzymes in the following reactions 
 
Component Volume/ 
50 ul reaction 
Component Volume/ 
50 ul reaction 
D-REEP1cDNA/ 
pcDNA3.1/Zeo(+) 
(50ng/ul) 
20 ul pUAST plasmid (100ng/ l) 5 ul 
EcoRI (10U/ul) 2 ul EcoRI (10U/ul) 2 ul 
XbaI (10U/ul) 2 ul XhoI (10U/ul) 2 ul 
10X L buffer 5 ul 10X L buffer 5 ul 
H2O to 50 ul  H2O to 50 ul  
Mixed products were incubated at 37°C for 1 hour and successively separated by 
electrophoresis through a 1% agarose gel. The bands corresponding to the H-REEP1 
cDNA and pUAST plasmid were cut from gel and purified using the QIAquick Gel 
Extraction Kit (Qiagen). Purified DNA products were eluted in 10 μl of elution buffer.  
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Transformation 
Ligation mixture was used for transformation of chemically competent DH5 alpha cells 
(Invitogen). Transformed bacteria were plated on LB–ampicillin agar plates and 
incubated overnight at 37°C.  
10 colonies were grown in LB medium with ampicillin. Plasmid DNA was successively 
purified by minipreparation protocol (Appendix A 3.8) and tested by restriction analysis 
for the right insertion. 
Plasmid purification  
D-REEP1/pUAST, P19R D-REEP1/pUAST, H-REEP1/pUAST, P19R H-
REEP1/pUAST, A132V H-REEP1/pUAST plasmids were purified from an overnight 
culture using a “Midi” plasmid purification kit, according to Qiagen Plasmid Midi 
purification protocols. The final pellet was re-suspended in 50 ul of TE buffer. 
3.3 REAL TIME PCR 
Set up reactions on ice. Volumes for a single 50-μl reaction are listed below.  
For multiple reactions, prepare a master mix of common components, add the 
appropriate volume to each tube or plate well on ice, and then add the unique reaction 
components. Preparation of a master mix is crucial in qRT-PCR to reduce pipetting 
errors. 
Component Single reaction 
SuperScript® III RT/Platinum® Taq Mix (includes RNaseOUT™)  1 μl  
2X SYBR® Green Reaction Mix      25 μl 
Forward primer, 10 μM       1 μl 
Reverse primer, 10 μM       1 μl 
ROX Reference Dye (optional)      1 μl/0.1 μl 
Template (1 pg to 1 μg total RNA)      ≤ 10 μl 
DEPC-treated water to       50 μl 
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To test for genomic DNA contamination of the RNA template, prepare a control 
reaction containing 2 units of Platinum® Taq DNA Polymerase (catalog no. 10966-018) 
instead of the SuperScript® III RT/Platinum® Taq Mix. 
 Cap or seal the reaction tube/PCR plate, and gently mix. Make sure that all components 
are at the bottom of the tube/plate; centrifuge briefly if needed. 
Place reactions in a preheated real-time instrument programmed as described above. 
Collect data and analyze results. 
Primers for D-REEP1 amplification: 
Forward primer    GCGGCCGCATGATCAGCAGCCTGTTTTC 
Reverse primer    CCAGTACATCATTCATTTAACATATTC 
Primers for rp49 housekeeping gene amplification: 
Forward primer   AGGCCCAAGATCGTGAAGAA 
Reverse primer    TCGATACCCTTGGGCTTGC 
 
3.4 CELLULAR BIOLOGY 
3.4.1 Cells culture 
HeLa cell culture was derived from a cervical carcinoma of a 31 years old african-
american woman. This was the first aneuploid line derived from human tissue 
maintained in continuous cell culture. 
COS7 cell line was obtained by immortalizing a CV-1 cell line derived from kidney 
cells of the African green monkey with a version of the SV40 genome that can produce 
large T antigen but has a defect in genomic replication. 
Propagation and subculturing 
HeLa and Cos7 cells were grown in complete DMEM medium (see Appendix B) with 
10% FBS serum and antibiotics, at 37°C in a CO2 incubator.  
Cells were passaged when growing logarithmically (at 70 to 80 % confluency) as 
follows: 
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 The cell layer was briefly washed twice with PBS to remove all traces of serum, then 
trypsin solution (see Appendix B) was added to flask and cells were observed under 
an inverted microscope until cell layer was dispersed (usually within 5 minutes). 
 Complete growth medium was added to stop trypsin action, cells were aspirated by 
gently pipetting and diluted 1:10 into a new flask with new complete medium.  
 For cell count, an aliquot of the cell suspension, before plating, was mixed 1:1 with a 
solution of 0.1% Trypan blue (Sigma) in PBS. Trypan blue is a vital stain used to 
selectively colour dead cells. In a viable cell Trypan blue is not absorbed, however it 
traverses the membrane in a dead one. Hence, dead cells are shown as a distinctive 
blue colour under a microscope. 10 ul of the above mixture was charged on a 
counting chamber and viable cells in the “counting squares” were counted. The cells 
density was calculated as follows: average of counted cells/ counting square X 10
4
 X 
dilution factor (=2) = number of cells/ml. 
3.4.2 Plasmid DNA Transfection 
To introduce expression plasmids into HeLa and Cos7 cells TransIT-LT1
®
 Transfection 
Reagent (Mirus) was used. Transfection Reagent is a mix of cationic lipids. The basic 
structure of cationic lipids consists of a positively charged head group and one or two 
hydrocarbon chains. The charged head group governs the interaction between the lipid 
and the phosphate backbone of the nucleic acid, and facilitates DNA condensation. The 
positive surface charge of the liposomes also mediates the interaction of the nucleic acid 
and the cell membrane, allowing for fusion of the liposome/nucleic acid (“transfection 
complex”) with the negatively charged cell membrane. The transfection complex is 
thought to enter the cell through endocytosis. Once inside the cell, the complex must 
escape the endosomal pathway, diffuse through the cytoplasm, and enter the nucleus for 
gene expression.  
Protocol 
In a six-well, one day before transfection, 2 x 10
5 
cells were plated in 1,5 ml of DMEM 
medium without antibiotics so that cells were 90-95% confluent at the time of 
transfection. 
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For each transfection sample, the complexes were prepared as follows: 
 DNA (2-3ug) was diluted in 250 μl of DMEM medium without antibiotics and serum 
and mixed gently. 
 TransIT-LT1 was mixed gently before use, then 8ul were diluted in 250 μl of DMEM 
medium without antibiotics and serum. The sample was incubated for 5 minutes at 
room temperature. 
 After the 5 minute incubation, the diluted DNA was combine with the diluted 
TransIT-LT1 (total volume = 500 μl), mixed gently and incubated for 20 minutes at 
room temperature. 
The 500 μl of complexes were added to each well containing cells and medium. 
Cells were incubated at 37°C in a CO2 incubator for 24 hours prior to testing for 
transgene expression.  
3.4.3 Immunocytochemestry (ICC) 
For immunocytochemistry, the day before transfection cells were plated on a glass 
coverslip previously sterilized with ethanol. 
The procedure used is divided into the below steps: 
Fixation 
One day after transfection, the cells were fixed in 4% paraformaldehyde in PBS pH 7.4 
for 10 minutes at room temperature. The cells were then washed tree times with PBS to 
eliminate paraformaldehyde. 
Permeabilization 
To permeabilize cell membranes and improving the penetration of the antibody, the 
cells were incubated for 10 minutes with PBS containing 0.1% Triton X-100 
(Applichem).  
Blocking and Incubation 
Cells were incubated with 10% serum in PBS for 10 minutes to block non specific 
binding of the antibodies.  
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Primary antibodies, diluted in PBS with 5% serum, were applied for 1 hour in a 
humidified chamber at 37°C. Cells were washed three times with PBS and then 
secondary antibodies, diluted in PBS, were applied for 1 hour in a humidified chamber 
at 37°C. 
Mounting and analysis 
Coverslips were mounted with a drop of the mounting medium Mowiol (Sigma). 
Images were collected with a Nikon C1 confocal microscope and analysed using 
either Nikon EZ-C1 (version 2.1) or NIH ImageJ (version 1.32J) softwares. 
Primary antibodies used Dilution 
Anti REEP1 rabbit (Proteintech Europe) 1:200 
Anti c-Myc rabbit (Sigma) 1:200 
Anti HA rabbit (Sigma) 1:200 
Anti c-Myc mouse (Sigma) 1:200 
Anti HA mouse (Sigma) 1:200 
Anti calnexin rabbit (Santa Cruz Biotechnology) 1:200 
Anti PDI mouse (BD biosciences) 1:100 
Anti GM130 mouse (BD biosciences) 1:200 
Anti-ubiquitin rabbit (Chemicon) 1:200 
Anti GM130 mouse (BD biosciences) 1:200 
Anti apo-B100 rabbit (Calbiochem) 1:100 
Anti-GFP mouse (Sigma Aldrich) 1:200 
Anti LAMP2 rabbit (Sigma Aldrich) 1:100 
Anti-ALDI rabbit (Acris Antibody) 1:100 
  
Secondary antibodies used Dilution 
DyLight
TM
488 anti rabbit (Jackson Immuno Research) 1:1000 
DyLight
TM
488 anti mouse (Jackson Immuno Research) 1:1000 
Cy
TM
3 anti mouse (Jackson Immuno Research) 1:1000 
DyLight
TM
549 anti rabbit (Jackson Immuno Research) 1:1000 
DyLight
TM
649 anti mouse (Jackson Immuno Research) 1:1000 
DyLight
TM
649 anti rabbit (Jackson Immuno Research) 1:1000 
  
Markers Dilution 
BODIPY 493/503 (Invitrogen) 1:1000 
Mito Tracker Orange CMTMRos (Invitrogen) 1:1000 
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3.4.4 Selective membrane permeabilization 
In order to determine the right topology of REEP1 protein, cells were selectively 
permeabilized for the plasma membrane and subsequently treated with protease. This 
assay is based on the accessibility of proteases to exposed polypeptides versus their 
inaccessibility to polypeptides that are located in protected intracellular regions such as 
the lumen of organelles. We use the cholesterol binding drug digitonin, a toxin derived 
from the plant Digitalis purpurea for the selective permeabilzation. The selectivity of 
this cell surface permeabilization results from the fact that the plasma membrane has the 
highest concentration of cholesterol, which renders the cell surface the prime target for 
digitonin intercalation with very few effects on intracellular membranes 
o Cells were transfected with pcDNA3.1 expressing GFP-REEP1 protein (GFP tag 
located at the N-terminal). 
o One day after transfection, the cells were washed cells three times for 1 min each in 
KHM buffer and fixed in 4% paraformaldehyde in PBS pH 7.4 for 10 minutes at 
room temperature  
o To permeabilize the plasma membrane, the same volume of KHM buffer containing 
digitonin 20 mM was added to the cells for 10–60 s.  
o  Cells were washed in KHM buffer (optional) and then 4–8 mM of the protease 
trypsin (in KHM buffer) was directly added on to the cells. 
o Primary antibodies, diluted in PBS with 5% serum, were applied for 1 hour in a 
humidified chamber at 37°C. Cells were washed three times with PBS and then 
secondary antibodies, diluted in PBS, were applied for 1 hour in a humidified 
chamber at 37°C 
3.5 BIOCHEMICAL TECHNIQUES  
3.5.1 Co-Immunoprecipitation (co-IP) 
Co-immunoprecipitation (Co-IP) is a common technique for protein interaction 
discovery. 
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An antibody for the protein of interest, linked to a support matrix, is incubated with a 
cell extract so that the antibody will bind the protein in solution. The antibody/antigen 
complex will then be pulled out of the sample: this physically isolate, from the rest of 
the sample, the protein of interest and other proteins potentially bound to it. The sample 
can then be separated by SDS-PAGE for Western blot analysis. 
In Co-IP experiments, anti-Myc agarose conjugate (Sigma) was used. Anti-c-Myc 
agarose conjugate is prepared with an affinity purified anti-c-Myc antibody coupled to 
cyanogen bromide-activated agarose. The purified antibody is immobilized at 1.0 to 1.5 
mg antibody per ml agarose. Anti-c-Myc antibody is developed in rabbit using a peptide 
corresponding to amino acid residues 408-425 of human c-Myc as the immunogen. 
Anti-c-Myc antibody recognizes the epitope located on c-Myc tagged fusion proteins 
and it reacts specifically with N- and C terminal c-Myc-tagged fusion proteins. 
The co-immunoprecipitation procedure used the following: 
 106 cells, plated on a six wells plate, were harvested using 0.5% Triton X-100 
(Applichem) in PBS, incubated in ice for 15 minutes and then centrifuged at 16000g 
for 15 minutes.   
 30 ul of anti-c-Myc agarose conjugate suspension was added to a microcentrifuge 
tube and washed 5 times with PBS by a short spin.  
 Cell extract (lysate) was added to the resin and incubated for 2 hours on an orbital 
shaker at room temperature. 
 At the end of incubation time, the supernatant was recovered and the resin was 
washed 5 times with PBS.  
 After the final wash, 70 ul of 1X Laemmli buffer (see Appendix B) were added to the 
resin and incubated at 95°C for 5 minutes. 
 After boiling, the sample was vortexed and then centrifugated for 5 seconds (pellet). 
 The presence of the c-Myc tagged protein and of other proteins potentially bound to 
it was detected in lysate, supernatant and pellet by Western blotting. 
3.5.2 Immunoisolation of membrane vesicles and membrane 
fractionation 
To obtain harbouring vesicles, the sample were prepared as follows:  
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 106 transfected cells, plated on a six wells plate, were suspended in homogenization 
buffer (10 mM HEPES-KOH buffer pH 7.4 containing 0.22 M mannitol, 0.07 M 
sucrose and protease inhibitors) and homogenized using a syringe with a 26-gauge 
needle. 
 Homogenate was sonicated and the supernatant containing vesiculated membranes 
recovered by centrifugation at 4000g for 5 minutes at 4°C in order to remove 
unbroken organelles. 
 When required, the vesiculated membranes were mixed with another pool of 
harbouring vesiscles and incubated at 30°C for 1 hour. 
 After incubation, immunoprecipitation of the harbouring vesicles was performed as 
described above (3.5.1). 
 The remaining supernatants containing vesiculated membranes were centrifugated at 
120000 g for 60 minutes to separate a membrane fraction (pellet) and a soluble 
fraction (supernatant). 
 Supernatant and pellet derived from the immunoprecipitation and 100000 g 
centrifugation were analysed by western blotting. 
3.5.3 REEP1 Membrane topology by membrane fractionation 
To determine the right membrane topology of REEP1 protein, membrane vesicles were 
isolated as above (chapter 1.3.2) and the sample was prepared as follow: 
The membrane fraction (pellet) was resuspended in homogenization buffer. The sample 
was divided into two parts: in one part of which 250 uM of protease K were added and 
incubated at 37°C for 15 minutes. The samples were analysed by western blotting. 
3.5.4 SDS PAGE 
SDS-PAGE stands for Sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis (PAGE) and is a method used to separate proteins according to their 
size. Since different proteins with similar molecular weights may migrate differently 
due to their differences in secondary, tertiary or quaternary structure, SDS, an anionic 
detergent, is used in SDS-PAGE to reduce proteins to their primary (linearized) 
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structure and coat them with uniform negative charges: proteins having identical charge 
to mass ratios are fractionated by size.  
 
Gel making 
The resolving gel was prepared with a 10% polyacrylamide content, while the stacking 
gel had a 5% acrylamide concentration. 
 
Components Resolving gel Stacking gel 
Acrylamide solution (Fluka) 10% (v/v) 5% (v/v) 
Tris-HCl pH 8.8 0.37M  
Tris-HCl pH 6.8  0.125M 
Ammonium persulphate 0.1% (w/v) 0.1% (w/v) 
SDS 0.1% (w/v) 0.1% (w/v) 
TEMED 0.02% (v/v) 0.02% (v/v) 
Sample preparation 
Samples were diluted in Laemli buffer (Appendix B) and then boiled at 95°C for 5 
minutes. 
Running the electrophoresis 
The amperage applied was 15mA/gel until the proteins reached the resolving gel, and 
then it was increased to 25mA/gel. 
Western blotting 
After the electrophoresis, the proteins were transferred from gel to PVDF membrane 
(Amersham Biosciences). 
The membrane was blocked with a solution of 10% milk in TBS-T (Appendix B) for 15 
minutes at room temperature on a shaking platform. 
The membrane was then incubated with the primary antibody diluted to the appropriate 
concentration in TBS-T and milk 2%, at 4°C O/N. 
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The secondary antibody diluted to the appropriate concentration in TBS-T was added 
and incubated for 1 hour at room temperature. 
The membrane detection was performed by ECL plus kit (Amersham Biosciences). 
Primary antibodies used Dilution 
Anti c-Myc mouse (Sigma) 1:1000 
Anti HA mouse (Cell Signalling) 1:1000 
Anti PDI mouse (BD biosciences) 1:500 
Anti calnexin rabbit (Millipore) 1:1000 
Anti caveoline rabbit ( Abcam)   1:1000 
Anti-α-actin mouse ( sigma)  1:1000 
 
Secondary antibodies used Dilution 
Anti mouse-HRP (Dako)  1:10000 
Anti rabbit-HRP (Dako)  1:10000 
3.6 DROSOPHILA MELANOGASTER LIFE CYCLE  
Fruit flies begin their lives as an embryo in an egg. This stage lasts for about one day. 
During this time, the embryo develops into a larva. The first instar larva hatches out of 
the egg, crawls into a food source, and eats. After a day, the first instar larva molts and 
becomes the second instar larva. After two days in this stage, the larva molts again to 
become the third instar larva. After three days of eating in this stage, the larva crawls 
out of the food source and molts again. Following this molt, the larva stops moving and 
forms a pupa. Drosophila stays in the pupa for about five days. During this time, the 
metamorphosis, or change, from larva to adult is occurring. Adult structures like wings, 
legs, and eyes develop. When the adults emerge from the pupa they are fully formed. 
They become fertile after about ten hours, copulate, the females lay eggs, and the cycle 
begins again. The whole life cycle takes about 12-14 days (Figure 3). 
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Figure 3. Drosophila melanogaster life cycle 
 
3.6.1 Microinjection 
Preparing the DNA for microinjection 
Injection mix  Final concentration 
Construct plasmid 3 μg/μl 
Helper plasmid 1 μg/μl 
10XMicroinjecting buffer  
(Appendix B 3.9) 
1X 
The mix is filtered through a 0.2 μm filter. 
The helper plasmid is a source of P-element transposase that allows the insertion of 
DNA construct into the fly genome. 
Fly strains  
A white mutant strain, w1118 (phenotype white eyes) was used in this protocol to allow 
detection of transgenic flies carrying white gene (phenotype red/orange eye). These flies 
were used both as a source of embryos for the injection and as a backcross stock to 
amplify the transformants.  
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Needles Preparation 
The quality of the needles is critical for high through-put. Needles should be pulled on 
any horizontal puller of the Sutter brand series using 1.0 mm OD borosilicate capillaries 
with omega dot fiber (WPI). The settings will be different for each machine and will 
need to be updated each time the heating filament is replaced or re-shaped, or a new 
type of capillaries is used. Several parameters influence the shape and properties of the 
needle and the effect produced by changing any of them (heat, velocity of pull, pressure 
of gas flow, number of steps) is difficult to predict. However, a paper by (Miller, 
Holtzman et al. 2002) is a very useful guideline for designing suitable needles. The 
needle should be progressively but shortly tapered and have no discontinuity or step. 
Needles that are too elongated will bend and brake when impaling the chorion. The 
condition used for our contruct microinjection are: Heat=414  Pull=200 Vell=250  
Time=150 
Embryo collection  
Embryos must be injected before blastoderm cellularization, a developmental stage that 
begins 45-50 minutes after eggs are laid at 22°C. Cellularization is easily visible at the 
microscope, and such old embryos should not be injected. They should be killed by 
piercing them with the injection needle. Injections should be performed during the first 
45 minutes after egg laying. 
Preparing the embryos 
Clean embryos were transferred in a small quantity of water to the centre of the 
coverslip with a clean thin pointed brush. 100 moist embryos were lined up with the 
dissection needle, one at a time, near one edge of the coverslip, with the posterior pole 
pointing to the edge. Embryos were let to dry for a few minutes to attach them firmly to 
the coverslip and then covered with as little halocarbon oil mix as possible. After 5-10 
min the oil has penetrated between the chorion and the vitelline membrane clearing the 
embryo and allowing a rough staging under the dissecting scope. 
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Microinjection  
The injection set-up consists of two parts: an inverted microscope (Nikon) equipped 
with a 20X lens and a micromanipulator InjectMan (Eppendorf) linked to the FemtoJet 
air-pressure injecting device (Eppendorf) connected to the needle holder. A set-up was 
installed in a cool room (18˚/20°C) to give more time flexibility as the embryos develop 
more slowly and the appropriate stage for injection lasts longer. The microinjection of 
the embryos was completely automatic, the needle was inserted quickly in the centre of 
the posterior pole were the germ cells will form, and pulled out quickly to avoid any 
leakage. 
After the injection 
Most of oil was drained off the coverslip and it was transferred to a food vial, placing 
the edge with the embryos against the food. The vials were kept at 18° C for two days 
then larvae were collected and transferred in vials of standard food and maintained at 
room temperature until adults hatched.  
Back-crossing the injected flies 
Hatching adults (F0) were separated by sex. Each male was crossed to 2 virgin w1118 
females and each female, even if obviously not virgin, to 2 or more w1118 males. 
Crosses were performed in separate vials of standard food. When at least 20-50 adult F1 
flies hatched in each vial they were screened to look for transformants individual. 
Transgenic flies (red eyes individuals) were crossed again with w1118 flies and with 
balancer lines. 
Characterization of transgenic lines 
F1 individuals may bear one transgene insertion on any of the chromosomes: X, II or 
III. Transgenes inserted on the fourth chromosome are very rare as this chromosome is 
rather small and essentially heterochromatic. 
The transgene should be immediately placed in front of a balancer chromosome, to 
avoid its loss. 
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If the insertion lays on the second chromosome the fly is crossed with the Sm6/TfT 
balancer stock (carrying the dominant morphological marker curly wing) as the schema 
reported below. 
 
Figure 4. Cross with II chromosome balancer 
 
If in F2 progeny there are individuals with white eyes the insertion is localized on 
another chromosome. 
If the insertion lays on the third chromosome, the fly is crossed with the TM3/TM6 
balancer stock (carrying the dominant morphological marker stubble hairs) as the 
schema reported below. 
 
Figure 5. Cross with III chromosome balancer 
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If in F2 progeny there are individuals with white eyes the insertion is localized on 
another chromosome.  
If the insertion lies on the X chromosome the fly is crossed with the Fm7/Sno balancer 
stock (carrying the dominant morphological marker heart- shaped eyes) as the schema 
reported below. 
If the insertion is occurred in the X chromosome, all the F1 females have w
+
/FM7 
phenotype. 
 
Figure 6. Cross with X chromosome balancer 
 
Drosophila genetics 
Drosophila strains used: elav-Gal4, D42-Gal4, GMR-Gal4, tubulin-Gal4, nanos- 
Gal4:VP16, UAS-mCD8-GFP (Bloomington); UAS-aCOP-RNAi, UAS-Sar1- RNAi 
(VDRC); MHC-Gal4; Mef2-Gal4; armadillo-Gal4; pUASp:Lys-GFPKDEL, 
pUASp:GalT-GFP and Sar1-GFP. Control genotypes varied depending on individual 
experiments, but always included promoter-Gal4/+ and UAS-transgene/+ individuals. 
3.7 TECHNIQUES FOR PHENOTYPIC ANALYSIS 
3.7.1 Immunohistochemistry 
Immunostaining was performed on wandering third instar larvae reared at 25°C.  
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Larvae dissection 
Wandering third instar larvae were raised at 25°C. After harvesting larvae, they were 
dissected dorsally in standard saline and fixed in 4% paraformaldeyde for 45 min. 
Preparations were subsequently washed in phosphate-buffered saline (PBS) containing 
0.5% bovine serum albumin.  
Antibodies  
The following antibodies were used: mouse anti-Myc (1:500, Cell Signaling), rabbit 
anti-Myc (1:200, Santa Cruz Biotechnology), mouse anti-HA (1:1,000, Cell 
 ignaling), rat anti-BiP (1:50, Babraham), mouse anti-p120 (1:600, Calbiochem), mouse 
anti-GFP (1:500, Roche), mouse anti-Dlg (1:100, DSHB), mouse anti-PDI (1:500, 
Stressgen), rabbit anti-calnexin (1:1,000, Millipore). Secondary antibodies for 
immunofluorescence (Cy5 and Cy3 conjugates from Jackson laboratories, Alexa Fluor 
488 conjugates from Invitrogen) were used at 1:1,000. Anti-mouse, anti-guinea pig and 
anti-rabbit 
Image analysis 
Confocal images were acquired through x40 or x60 CFI Plan Apochromat Nikon 
objectives with a Nikon C1 confocal microscope and analysed using the NIS 2. 
METHODS 44. 
Elements software (Nikon). Figure panels were assembled using Adobe 
Photoshop CS4. 
3.7.2 Electron microscopy 
Drosophila third instar larva brains were fixed in 4% paraformaldehyde and 2% 
glutaraldehyde and embedded as described. EM images were acquired from thin 
sections under a FEI Tecnai-12 electron microscope. EM images of individual neurons 
for the measurement of the length of ER profiles were collected from three brains for 
each genotype. At least 20 neurons were analyzed for each genotype. Quantitative 
analyses were performed with ImageJ software 
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HRP conjugates from DACO were used at 1:10,000 Image analysis 
Images were collected with a Nikon C1 confocal microscope and analyzed using either 
Nikon EZ-C1 (version 2.10) or NIH ImageJ (version 1.32J) softwares.  
3.7.3 Drosophila Driver lines  
D-REEP1 and H-REEP1 transgenic lines were tested using different Gal4 driver lines. 
The Gal4 activator lines used in this study were GMR-Gal4, Tubulin-Gal4, Elav-Gal4, 
MEF2-Gal4 and D42-Gal4 (Bloomington Stock Center, Indiana University). All 
experimental crosses were performed at 25°C. 
3.8 APPENDIX A: GENERAL PROTOCOLS 
Transformation of chemiocompetent cells 
o Gently thaw the chemiocompetent cells on ice. 
o Add ligation mixture to 50 μl of competent cells and mix gently. Do not mix by 
pipetting up and down. 
o Incubate on ice for 30 minutes. 
o Heat-shock the cells for 30 seconds at 42°C without shaking. 
o Immediately transfer the tube to ice. 
o Add 450 μl of room temperature S.O.C. medium. 
o Cap the tube tightly and shake the tube horizontally (200 rpm) at 37°C for 1 
hour. 
o Spread 20 μl and 100 μl from each transformation on prewarmed selective plates 
and incubate overnight at 37°C.  
Preparation of plasmid DNA by alkaline lysis with SDS: minipreparation 
Plasmid DNA may be isolated from small-scale (1-3 ml) bacterial cultures by treatment 
with alkali and SDS.  
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o Inoculate 3 ml of LB medium (Appendix B) containing the appropriate 
antibiotic with a single colony of transformed bacteria. Incubate the culture 
overnight at 37°C with vigorous shaking. 
o Pour 1.5 ml of the culture into a microfuge tube. Centrifuge at maximum speed 
for 30 seconds in a microfuge. Store the unused portion of the original culture at 
4°C.   
o When centrifugation is complete, remove the medium by aspiration, leaving the 
bacterial pellet as dry as possible. 
o Resuspend the bacterial in 100 μl of ice-cold Alkaline lysis solution I (Appendix 
B) by vigorous vortexing. 
o Add 200 μl of freashly prepared Alkaline lysis solution II (Appendix B) to each 
bacterial suspension. Close the tube tightly, and mix the contents by inverting 
the tube rapidly five time. Do not vortex. Store the tube on ice. 
o Add 150 μl of ice-cold Alkaline lysis solution III (Appendix B). Close the tube 
and disperse Alkaline lysis solution III through the viscous bacterial lysate by 
inverting the tube several times. Store the tube on ice 3-5 minutes. 
o Centrifuge the bacterial lysate at maximum speed for 5 minutes at 4°C in a 
microfuge. Transfer the supernatant to a fresh tube. 
o Precipitate nucleic acids from the supernatant by adding 2 volumes of ethanol at 
room temperature. Mix the solution by vortexing and then allow the mixture to 
stand 2 minutes at room temperature. 
o Collect the precipitate of nucleic acid by centrifugation at maximum speed for 
10 minutes at 4°C in a microfuge. 
o Remove the supernatant by gentle aspiration. Stand the tube in an inverted 
position on a paper towel to allow all of the fluid to drain away. Use a pipette tip 
to remove any drops of fluid adhering to the walls of the tube 
o Add 2 volumes of 70% ethanol to the pellet and invert the closed tube several 
times. Recover the DNA by centrifugation at maximum speed for 5 minutes at 
4°C in a microfuge. 
o Again remove all the supernatant by gentle aspiration. 
o Dissolve the nucleic acids in 50 ul of TE buffer (pH 8.0) or distillated 
autoclavated water containing 20 ug/ml DNase-free RNase A (pancreatic 
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RNase). Vortex the solution gently for a few seconds. Store the DNA solution at 
-20°C. 
3.9 APPENDIX B: STOCKS AND SOLUTIONS 
LB Medium (Luria-Bertani Medium) 
Bacto-tryptone 10g 
Yeast extract 5g 
NaCl 10g 
H2O to 1 Liter 
Autoclave. 
 
LB Agar  
Bacto-tryptone 10g 
Yeast extract 5 g 
NaCl 10 g 
Agar 20g 
H2O to 1 Liter 
Adjust pH to 7.0 with 5 N NaOH. Autoclave.  
LB–Ampicillin Agar  
Cool 1 Liter of autoclaved LB agar to 55° and then add 10 ml of 10 mg/ml filter-
sterilized Ampicillin. Pour into petri dishes (~25 ml/100 mm plate). 
 
SOC medium 
Bacto-tryptone 20g 
Yeast extract 5 g 
NaCl 0,5 g 
KCl 1M 2,5 ml 
H2O to 1 Liter 
Adjust pH to 7.0 with 10N NaOH, autoclave to sterilize, add 20 ml of sterile 1 M 
glucose immediately before use. 
Alkaline lysis solution I 
Glucose 50 mM 
Tris HCl 25 mM (pH 8.0) 
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EDTA 10 mM (pH 8.0) 
Solution I can be prepared in batches of approximately 100 ml, autoclaved for 15 
minutes and stored at 4 °C.  
 
Alkaline lysis solution II 
NaOH 0.2 N (freshly diluted from a 10 N stock) 
SDS 1% (w/v) 
 
Alkaline lysis solution III 
Potassium acetate 3 M 
Glacial acetic acid 11.5% (v/v) 
 
TE Buffer 
Tris-HCl 10 mM (pH 7.5) 
EDTA 1 mM 
 
DMEM complete medium 
DMEM 4.5g/L Glucose with  L-Glutamine (Lonza) 
FBS 10% (v/v) 
Penicillin-Streptomycin mixture 100X (Lonza, contains 5000 units potassium penicillin 
and 5000 ug streptomycin sulfate) 
 
Phoshate Buffered Saline (PBS) 
KH2PO4 1444 mg/L
 
NaCl   9000 mg/L 
Na2HPO4 
 
795 mg/L 
Trypsin solution 
Trypsin 2,5% 10X (Lonza) 
 
 
Running buffer 1X 
Tris 25mM 
Glycine 250mM 
SDS 0.1% 
In deionized H2O  
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Transfer buffer 1X 
Tris 25mM 
Glycine 192mM 
In deionized H2O  
TBS-T buffer 1X 
Tris 100mM 
NaCl 1,5M 
Tween-20 1% 
In deionized H2O  
Laemmli buffer 2X 
SDS 4% 
Glycerol 20% 
2-mercaptoethanol 10% 
Bromphenol blue 0,004%  
Tris HCl 125mM  
The solution has a pH of approximately 6.8 
10X injection buffer: 
Sodium Phosphate Buffer pH 6.8 0.1M 
KCl 5Mm 
 
Drosophila’s food 
Agar 15 g 
Yeast extract 46.3 g 
Sucrose 46.3 g 
H2O to 1 Liter 
Autoclave and then add 2 g of Nipagine dissolved in 90% ethanol.  
Egg laying food 
Agar 6 g 
Sucrose 6.6 g 
Fruit juice 66 ml 
H2O to 200ml 
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3.10 APPENDIX C: PLASMIDS 
pDrive cloning vector (Qiagen) 
The pDrive Cloning Vector provides superior performance through UA-based ligation 
and allows easy analysis of cloned PCR products. 
This vector allows ampicillin and kanamycin selection, as well as blue/white colony 
screening. The vector contains several unique restriction endonuclease recognition sites 
around the cloning site, allowing easy restriction analysis of recombinant plasmids. 
The vector also contains a T7 and SP6 promoter on either side of the cloning site, 
allowing in vitro transcription of cloned PCR products as well as sequence analysis 
using standard sequencing primers. In addition, the pDrive Cloning Vector has a phage 
f1 origin to allow preparation of single-stranded DNA  
pcDNA3.1/Zeo(+) (Invitrogen) 
pcDNA3.1/Zeo (+) is an expression vector, derived from pcDNA3.1, designed for high-
level stable and transient expression in a variety of mammalian cell lines.  
To this aim, it contains Cytomegalovirus (CMV) enhancer-promoter for high-level 
expression; large multiple cloning site; Bovine Growth Hormone (BGH) 
polyadenylation signal; transcription termination sequence for enhanced mRNA 
stability and  Zeocin resistance coding region. 
pUAST vector 
pUAST is a P-element based vector that allows one to place the gene of interest under 
GAL4. pUASt consists of five tandemly arrayed optimized GAL4 binding sites 
followed by the hsp70 TATA box and transcriptional start, a polylinker containing 
unique restriction sites and the SV40 small T intron and polyadenylation site. These 
features are included in a P-element vector (pCaSpeR3) containing the P-element ends 
(P3’ and P5’) and the white gene which acts as a marker for successful incorporation 
into the Drosophila genome  
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3.11 APPENDIX D: CLINICAL PHENOTYPES OF HSP MUTATIONS 
CONSIDERED IN THIS STUDY 
Patients carrying REEP1 p.P19R mutation presented an HSP pure, autosomal dominant 
form, with an early onset age. Clinical features of this patients are: severe spasticity, 
moderate weakness.  
Patients carrying REEP1 p.D56N mutation presented an HSP pure, autosomal dominant 
form, with an early onset age. Clinical features of this patients are: moderate spasticity 
and weakness. 
Patients carrying REEP1 p.A132V mutation presented an HSP pure, autosomal 
dominant form, with an late onset age. Clinical features of this patients are: slightly 
spasticity and weakness 
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4. RESULTS 
4.1 4.1 CHARACTERIZATION OF THE DROSOPHILA HOMOLOG 
OF SPG31 (H-REEP1) 
Using the amino acid sequence of human REEP1 protein isoform 1, we searched the 
whole Drosophila genomic sequence to identify homologous proteins employing the 
Blast software in the Flybase website (flybase.bio.indiana.edu/blast/). The blast search 
produced a highly significant alignment of human REEP1 to the protein encoded by the 
CG42678 gene (Figure 7). Similar to the human homolog, CG42678 consists of more 
than one alternative splicing isoform. It encodes nine annotated transcripts, CG42678-
PD (435 aa), CG42678-PE (288 aa), CG42678-PG (288 aa), CG42678-PH (569 aa), 
CG42678-PI (716 aa), CG42678-PJ (570 aa), CG42678-PK (408 aa), CG42678-PL (151 
aa), CG42678-PO (291 aa). The CG42678 gene (D-REEP1) localizes on the second 
chromosome. As reported in Drosophila data base, CG42678 gene has an expression 
peak observed within 12-18 embryonic stages and throughout the pupal period. 
 
 
Figure 7. Schematic representation of D-REEP1 gene. The Drosophila homolog of H-REEP1 gene, 
localize on the second chromosome and codifies nine transcript isoformes. 
CG 42678
CG 42678-RG
CG 42678-RJ
CG 42678-RH
CG 42678-RE
CG 42678-RD
CG 42678-RO
CG 42678-RI
CG 42678-RL
CG 42678-RK
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Based on protein sequence alignment the CG42678-PG and the CG42678-PE are 
translated into the same polypeptide. This two isoforms show the highest homology 
with human REEP1, displaying a 67% of identity and 81% of similarity. Human REEP1 
consists of two putative transmembrane domains and a conserved protein domain, 
TB2/DP1/HVA22 of unknown function. Domain sequence analysis showed that all of 
these domains are conserved in the Drosophila homolog (Figure 8). In order to alter the 
expression of D-REEP1 in a targeted manner in different tissue of Drosphila, we 
generated multiple, independent transgenic lines for the overexpression of the wild-type 
protein. Based on the existing genomic sequence, we have designed oligonucleotide 
primers to amplify the D-REEP1 transcript CG42678-PG, the most similar form to H-
REEP1 and generated the corresponding cDNA. For this purpose reverse transcription 
experiments were carried out on total RNA isolated from heads of wild type adults and 
subsequently D-REEP1 was cloned into pUAST plasmid for P-element mediated 
transgenic insertion. 
 
Figure 8. Alignment of human and Drosophila REEP1 protein sequence. The conserved amino acids 
are in red, blu and red boxes are the conserved domain of the protein. 
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4.2 D-REEP1 LOCALIZES TO THE ER  
To determine D-REEP1 subcellular localization we generated transgenic Drosophila 
lines for expression of D-REEP1 fused with c-Myc tag at the C-terminal of the protein. 
We used an antibody against Myc tag for the immunolocalization of D-REEP1 protein. 
Immunohistochemistry experiments performed on third instar larva expressing 
ubiquitously UAS-D-REEP1 under the control of the tubulin-Gal4 driver showed that 
D-REEP1 signal overlapped the ER specific marker GPF-KDEL (Figure 9). To further 
confirm the D-REEP1 localization to the ER, we isolated the membrane fraction from 
cell homogenate. For this purpose the D-REEP1 cDNA was cloned in pcDNA3.1 for 
expression in mammal cell culture. We expressed D-REEP1 in HeLa cells. Transfected 
cells were homogenized in the absence of detergent and fragmented membranes were 
vesiculated by sonication. Fractionation of cleared cell homogenates showed that D-
REEP1 and the ER integral membrane protein calnexin partitioned exclusively to the 
membrane fraction (Figure 9). These data demonstrates that D-REEP1, like the Human 
homolog, is an integral ER membrane protein. 
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Figure 9. D-REEP1 localizes on ER membranes. (a) ) Immunocytochemistry of third instar larval 
ventral ganglion (NSC) with anti Myc to label D-REEP1 expression GFP-KDEL to label the ER marker 
(b) Immunocytochemistry on third instar larva body wall muscles. D-REEP1 localizes with the ER 
marker KDEL. (c) Western blot analysis of the soluble and membrane fractions from HeLa homogenates 
over-expressing D-REEP1 protein. D-REEP1 band was detected at membrane fraction corresponding to 
ER together with ER membrane protein calnexin. Scale bar 20 µm. 
 
 
4.3 CHARACTERIZATION OF D-REEP1 LOSS OF FUNCTION 
MUTANT 
In order to study the biological role of D-REEP1 we analyzed a transgenic line, 
CG42678 
EP2014
, containing a transposable P-element insertion in the first intron of the 
D-REEP1 gene. Insertions of P-elements in introns could affect transcription rates, 
alternative transcription start or stop sites, or the frequencies of different splicing 
patterns. Various P-element insertions have been reported to increase or decrease 
transcription rates or to change the timing or the location of expression. (Leland 
Hartwell et al. 2004). To verify the genomic insertion of the P-element, we extracted the 
genomic DNA from CG42678 
EP2014
 flies and effectuated a direct sequencing (Figure 
10). This analysis confirmed the P element insertion in the first intron of CG42678 
gene, in the genomic DNA.  
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Figure 10. DNA chromatogram sequence of P element insertion site. Black boxes show the P element 
insertion in to the genome DNA of CG42678
EP2014
 flies. 
 
In order to determine whether the presence of this P element could affect the CG24678 
transcripts expression levels we performed a semi-quantitative RT PCR analysis from 
CG42678 
EP2014
 flies. In a semi-quantitative PCR the PCR product is measured within 
the exponential phase of the PCR reaction, where the amount of amplified target is 
directly proportional to the input amount of target. Therefore the PCR must be carried 
out during the exponential phase (between cycles 25 and 30) of the PCR reaction and 
the plateau phase (>30 cycles) must be avoided. Total RNA was extracted from 
CG42678
EP2014
 and wild type flies, and semi-quantitative PCR was performed for target 
gene, D-REEP1 and a housekeeping gene, D-GDPH. The amplified product were 
resolved in agarose gel and the band intensity signal was analyzed with ImageJ software 
(Java based program for image analysis, developed at the National Institute of Health). 
After RT-PCR of 35 cycles a band detectable in agarose gel, corresponding to D-
REEP1 cDNA was amplified from both mutant and wild type RNA extract. However, 
after RT-PCR of 25 cycles D-REEP1 cDNA corresponding band, was not amplified 
from total RNA extracted from CG42678 
EP2014
 flies. We analysed the band intensity 
signal of D-REEP1 cDNA PCR product compared to D-GDPH cDNA levels (Figure 
11). This analysis showed that CG42678
EP2014 
have a significantly lower D-REEP1 
cDNA levels that wild type flies.  
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To further confirm this result we performed a Real Time PCR analysis. Total RNA was 
extracted from adults CG42678 
EP2014
 and wild type flies and analyzed. Real Time PCR 
was performed for D-REEP1 gene and rp49 as housekeeping gene. The result obtained, 
confirmed the semi-quantitative PCR data. CG42678
EP2014 
 flies showed a reduction of 
D-REEP1 mRNA levels to about 2% of its endogenous levels. (Figure 11). These data 
indicate that the P-element insertion in the first intron reduces the expression level of 
the D-REEP1 mRNA. 
 
Figure 11. D-REEP1 expression levels. (a) Semiquantitative RT-PCR analysis of 35 cycles, 30 cycles 
and 25 cycles of amplification for D-REEP1 and D-GDPH as control, in wild type (1) and CG42678
EP2014
 
flies (2). (b) D-REEP cDNA expression compared to D-GDPH, based on PCR band intensity. (c) Bar 
graph illustrating real time PCR, data demonstrating a reduction of D-REEP1 mRNA in CG42678
EP2014 
flies compared to the host gene rp49. Assays were performed in triplicate and results shown are 
representative of two independent experiments. 
 
Phenotypic analysis of D-REEP1
EP2014
 flies showed that these mutants, though viable, 
display a developmental delay and exhibit morphological alterations of the wings. We 
compared the wings area of D-REEP1 mutant flies to the wings area wild type. As 
shown in figure 12, D-REEP1 mutant flies presented oversized wings. Measurement of 
wing area showed that D-REEP1 mutant flies wings are about 20% larger of wings of 
wild type flies. To demonstrate that the oversized wing phenotype was due to loss of D-
REEP1 we performed rescue experiments by expressing wild type D-REEP1 in the D-
REEP1 mutant background. In 90% of the cases, the presence of D-REEP1 rescued the 
phenotype, indicating that oversized wings of mutant flies is caused by loss of D-
REEP1 (Figure 12).  
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Figure 12. Mutants CG42678
EP2014 
wings phenotype. (a) In this panel are shown wings of wilde type fly 
(W1118), and wings of D-REEP1 mutant flies. (b) Graph analysis of the area of the wings of wild type 
flies and D-REEP1 mutant flies. D-REEP1 mutant flies displayed oversize wings of 20% compared to 
control. (c) Expression of wild type D-REEP1 protein rescued wings phenotype in D-REEP1 mutant 
background. Wild type D-REEP1 was expressed at 25°C using ubiquitous driver actin-Gal4. (d) Graph 
analysis of rescue wings area phenotype. Error bars represent s.d.; * p<0.000001 
 
 
4.4 LOSS OF D-REEP1 FUNCTION INDUCES ER 
MORPHOLOGY ALTERATION  
H-REEP1 is an ER protein structurally related to the DP1/ Yop1 family of proteins 
involved in ER shaping. It forms molecular complexes with other two HSP related 
proteins, spastin and atlastin-1, to coordinate ER shaping in corticospinal neurons. 
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Therefore we wanted to define in more detail the morphology of the ER membrane in 
the nervous system of D-REEP1
EP2014
 mutant flies. We performed electron microscopy 
(EM) and visualized the neuronal ER in third instar larva brains. Ultra structural 
analysis of the ER revealed significant morphological variations of the ER in neurons of 
D-REEP1 mutant flies (Figure 13). ER profiles of D-REEP1 loss of function neurons 
display an alteration of ER length compared to ER profiles of wild type neurons (Figure 
13). Control neurons displayed ER profiles with average length 742±54 nm, whereas 
neurons lacking D-REEP1 showed elongated ER profiles, 1334±71 nm. Moreover, ER 
profile size distribution analysis, in wild type neuron, revealed that most representative 
class of ER profiles length is between 500-1000 nm, whereas in neurons lacking D-
REEP1 three classes of long ER profiles were observed (1000 nm-1500 nm, 1500-2000 
nm, >2000 nm. The two last classes of ER length profiles (1500-2000 nm, >2000 nm) 
were virtually absent in control neurons (Figure 13). In addition, in about 20% of D-
REEP1 loss of function neuronal cells, a modification of normal luminal width of the 
ER was observed (Figure 13). 
To demonstrate that the alteration of ER morphology was due to loss of D-REEP1 we 
performed rescue experiments by expressing wild type D-REEP1 in the D-REEP1 
mutant background. The presence of D-REEP1 rescued ER profile length, indicating 
that loss of D-REEP1 alters ER morphology (Figure 14). 
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Figure 13. Loss of D-REEP1 cause ER length modification. a) Graph analysis of ER average length of 
ER profiles. Error bars represent s.d.; * p<0.000001. b) Difference in size distribution of ER profiles c). 
Electron microscopy images of third instar larva brains, show ER with typical tubular structure in control 
neurons and D-REEP1 loss of function neurons (n, nucleus; m, mitochondria, white arrows indicate ER). 
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Figure 14. Expression of wild type D-REEP1 rescues ER length profiles in the D-REEP1 mutant null 
background. Wild type D-REEP1 was expressed at 25°C using the ubiquitous driver actin-Gal4. (a) representative 
EM images of third instar larva brains (n,nucleus; m, mitochondria; white arrows indicate ER). (b) Average ER 
profile length. Error bars represent s.d; * p<0,000001. (c) Difference in size distribution of ER profiles 
4.5 D-REEP1 LOSS OF FUNCTION MUTANT HAS REDUCED 
LIPID STORAGE.  
Animals homozygous for D-REEP1
EP2014
 are viable but homozygous mutant larvae 
display a growth delay and reach pupation with a delay by one day compared to wild 
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type controls. This resulted in pupa about 17% smaller than controls. In addition during 
larvae dissection we noticed that D-REEP1 mutant larvae show a reduction of total fat 
compared to the wild type (Figure 15). We decided to focus our attention on the fat 
body, which is the adipose tissue of insects and also has liver-like activity due to its 
detoxification function since it plays an important role in larva growth regulation 
(Colombani et al.2003). Moreover, fat body is shown to act as an endocrine tissue that 
controls the growth of imaginal discs (structure that store precursor cells of adult 
structures such as eyes, antennae, legs, wings, halteres and genitalia) by releasing 
growth hormones (Kawamura et al.1999). Therefore, we systematically investigated if 
in D-REEP1 mutants there were alterations in lipid storage. Within the cells lipid are 
stored in specific organelle, the lipid droplets (LDs). We used BODIPY 493/503 dye to 
stain the lipid droplets in the fat body of wandering third instar larvae. Dissection of the 
larval fat body of D-REEP1 mutant and staining with a lipid droplet marker, BODIPY 
493/503, revealed that the number of lipid droplets in fat body cells is significantly 
reduced, in contrast to wild type fat bodies which have many large lipid droplets (Figure 
15). We than decided to perform lipid staining in other tissues of D-REEP1 mutants, 
including wing disc and muscle. Similar to the fat body, D-REEP1 mutants have 
reduced lipid storage in the imaginal wing disc.  
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Figure 15. D-REEP1 loss of function mutants show a reduce lipid storage. (a) Third instar larvae 
dissection of wild type and D-REEP1 loss of function mutant. D-REEP1 mutants display a less fat 
quantity. (b) BODIPY 493/503 staing of lipid storage in fat body cells of wild type and D-REEP1 loss of 
function mutant. (c) Intensity analysis of BODIPY 493/503 staining for lipid droplets of imaginal disc. 
(d) Graph analysis of third instar larvae body size of D-REEP1 loss of function mutant and wild type flies. 
Scale bar: 20 µm. Error bars represent s.d, * p<0,0001 
Several proteins implicated in neurodegenerative diseases have recently been linked to 
the regulation of neutral lipid storage. For instance HSP related protein like seipin and 
spartin are involved in lipid droplets biogenesis and LDs turnover. Neutral lipid 
deposition and lipid droplet formation seems to have a role in neuronal functions, and it 
may be particularly important under stress conditions. Therefore, we wanted to analyze 
in greater detail if in the nervous system of D-REEP1 loss of function mutants there 
were variations in LDs storage. After dissection and lipid staining we observed that, 
unexpectedly, even in nervous system, D-REEP1 mutants, presented a reduced number 
of lipid droplets. (Figure 16). We measured the reduction of LDs number in the nervous 
system of D-REEP1 mutants, by counting the LDs number in the axon of muscle 4 
neuromuscular junction (NMJs) of segments A2. In a wild type larvae the average 
number of LDs in the axons is 0,1 LDs/µm
2
 while in D-REEP1 mutant there is a 
significant decrease to 0,04 LDs/µm
2
. Changes in LDs size in D-REEP1 mutants may 
reflect changes in lipid levels. Moreover, we examined the total triglyceride (TAG) 
content and found that the triglycerides level in D-REEP1 mutants is greatly reduced 
compared to control animals (Figure 16). The TAG level in D-REEP1 mutants turned 
out to be 70% that of wild type. Under starved conditions animals can mobilize stored 
lipid from LDs. Animals with high levels of TAG are resistant to starvation, while 
animals with low levels of TAG may be sensitive to starvation. We than starved flies 
adult of D-REEP1 mutants and wild type. We found that D-REEP1 mutants died after 
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48 hours of starvation while about 60% of wild type were still alive after the same 
period of time. These results further confirm a reduction of lipid droplets levels in D-
REEP1 mutants (Figure 16) 
 
 
 
Figure 16. D-REEP1 loss of function mutant have a reduced lipid storage. (a) Representative muscle 
4 NMJs of segments A2 of third instar larvae immunostained with anti-HRP to label the axon and the 
NMJ, and BODIPY 493/503 for LDs staining. (b) Bar graph analysis of lipid droplets number in the 
axons muscle 4 of NMJs of segments A2 of third instar larvae for D-REEP1 loss of function mutant and 
control. (c) Bar graph showing total triglycerides levels of wild type and D-REEP1 loss of function 
mutant. (d) Adult starvation assay. The x-axis shows the hours of starvation and the y-axis shows the 
survival rate. Scale bar: 10 µm. Error bars represent s.d, * p<0,0001 
 
To evaluate whether this alteration of lipid droplets number in the neuromuscular 
junction of D-REEP1 mutant larvae was due to loss of D-REEP1, we over expressed 
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wild type D-REEP1 in the mutant background. The presence of the wild type protein 
increased the number of LDs in D-REEP1 mutant background, suggesting that loss of 
D-REEP1 alters the quantity of LDs in Drosophila axons (Figure 17). 
 
 
Figure 17. Expression of wild type D-REEP1 rescue the reduced lipid droplets number phenotype in 
D-REEP1 mutant background. Wild type D-REEP1 was expressed at 25°C using ubiquitous driver 
actin-Gal4. (a) Representative muscle 4 NMJs of segments A2 of third instar larvae immunostained with 
anti-HRP to label the axon and the NMJ, and BODIPY 493/503 for LDs staining. (d) Graph analysis of  
lipid droplets number in the axon of muscle 4 of NMJs of segments A2 of third instar larvae. Error bars 
represent s.d.; * p<0.0001. Scale bar: 10 µm 
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4.6 D-REEP1 OVEREXPRESSION RESULTS IN REDUCED SIZE 
OF LIPID DROPLETS 
We overexpressed in Gal4-mediated manner UAS-D-REEP1-Myc with a number of 
ubiquitous and tissue specific promoters. Flies overexpressing D-REEP1 are viable, 
fertile and without any visible morphological phenotype. Since loss of D-REEP1 
protein led to an increase of ER length and altered the ER morphology, we wanted to 
analyze in more detail the ER in flies overexpressing D-REEP1. Confocal microscopy 
analysis of third instar larvae expressing ubiquitously D-REEP1 under the control of 
tubulin-Gal4/GFP-KDEL driver shows a morphologically normal ER in the nervous 
system. In the muscle of these larvae we observed an accumulation of the ER marker 
GFP-KDEL (Figure 18). To investigate in more detail the ER morphology and to 
analyze these accumulation we used electron microscopy (EM) and visualized the 
neuronal ER in third instar larva brains overxpressing D-REEP1. However, 
ultrastructural analysis did not show any significant changes of ER length profiles or ER 
morphology of neurons overexpressing D-REEP1 (Figure 18).  
Because of the reported lipid droplets D-REEP1 loss of function phenotype, we asked 
whether overexpression of D-REEP1 could also influence lipid droplet number. Our 
analysis focused on the lipid droplets in neuronal cells. To examine the effects on lipid 
droplets we expressed D-REEP1 ubiquitously using the actin-Gal4 driver. The 
expression of D-REEP1 did not change the number of LDs number in the axons, but 
unexpectedly we observed a modification of LDs size. In wild type larvae the lipid 
droplet display an average diameter of 0.76 nm while in larvae expressing D-REEP1 the 
average diameter of lipid droplets is decreased to 0,56 nm 
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Figure 18. Expression of wild type D-REEP1 in vivo. (a) Immunocytochemistry of third instar wall 
muscle with anti Myc to label D-REEP1 expression GFP-KDEL to label the ER marker. Expression of 
wild type D-REEP1 induce accumulation of ER marker GFP-KDEL in wall muscle of third instar larvae. 
(b) Electron microscopy images of third instar larva brains, show ER with typical tubular structure in both 
control neurons and in neurons expressing D-REEP1, (n, nucleus; m, mitochondria, white arrows indicate 
ER. c) Graph analysis of ER average length of ER profiles. No significant changes were observed. Error 
bars represent s.d. n>100. Scale bar 20µm. 
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Figure 19. Expression of D-REEP1 wild type reduces the lipid droplets size. (a) 
Immunocytochemistry of third instar larval neurons with HRP to label the neuronal membranes, anti Myc 
to label D-REEP1 expression and BODIPY 493/503 to label lipid droplets. (b) Graph analysis of LDs 
radius in neurons of wild type and neuron expressing D-REEP1. (c) Distribution of lipid droplets size 
profiles. Error bars represent s.d.; * p<0.0001. Scale bar: 10 µm 
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4.7 D-REEP1 P19R PATHOLOGICAL MUTATION LOCALIZE 
ON LDS 
To establish Drosophila as a model system for H-REEP1 linked spastic paraplegia and 
try to understand the pathogenic mechanism underlying H-REEP1 mutations, we have 
introduced by site-directed mutagenesis a disease mutation, P19R, in the D-REEP1 
cDNA. H-REEP1 p.P19R (c.56C>G) is a missense mutation localized at the first 
transmembrane domain of H-REEP1 protein (Beetz et al. 2008). The degree of 
homology of D-REEP1 with the human protein is so remarkable that the great majority 
of disease causing missense mutations occur in conserved aminoacid residues. We 
generated transgenic Drosophila lines for the expression of D-REEP1-P19R under the 
control of the ubiquitous and tissue specific Gal4 drivers lines. The P19R substitution 
was introduced in the D-REEP1 cDNA and its presence was confirmed by sequence 
analysis. To generate Drosophila transgenic lines, the mutated cDNA was introduced in 
the pUAST vector, in frame at the 3’ terminal with a Myc tag. To study the effects of in 
vivo of D-REEP1-P19R we expressed the protein under the control of the ubiquitous 
driver line tubulin-Gal4. Confocal microscopy analysis of third instar larvae showed 
that while the wild type protein D-REEP1 is an ER protein, D-REEP1-P19R co-
localized predominantly with the LDs marker BODIPY 493/503 (Figure 20). In 
addition, quantification analysis of LDs in the axons revealed that expression of D-
REEP1-P19R reduced significantly the number of lipid droplets. In wild type larvae 
axons the number of lipid droplets was about 0,10 LDs/µm
2
 , while in larvae expressing 
D-REEP1-P19R, the number of lipid droplets in the axons was about 0,03 LDs/µm
2
. 
The LDs number in the nervous system of larvae expressing D-REEP-P19R mutant 
form was even lower that LDs number of D-REEP1 loss of function mutant. In contrast, 
in larvae expressing D-REEP-P19R, we observed an increase in the size of lipid 
droplets. In larvae expressing D-REEP1-P19R the average diameter of lipid droplets 
was increased to 1,16 nm (Figure 20) 
Even thought D-REEP1-P19R localized predominantly in LDs, we decided to analyze 
also ER morphology by electron microscopy. This analysis reveled that there were no 
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alterations of ER length profiles in the neuron expressing D-REEP1-P19R. However 
some morphological changes in luminal width were observed as shown in figure 21. 
 
 
Figure 20. Expression of D-REEP1-P19R increases the size of lipid droplets reduces their number 
in Drosphila nervous system. (a) Immunocytochemistry of third instar larval neurons with HRP to label 
the neuronal membranes, anti Myc to label D-REEP1-P19R expression and BODIPY 493/503 to label 
lipid droplets. (b) Graph analysis of LDs radius in neurons of wild type and neurons expressing D-
REEP1-P19R mutated form. (c) Graph bar showing the average number of LDs in wild type and in 
neuron expressing D-REEP1-P19R muted form. (d) Distribution of lipid droplets size profiles. Error bars 
represent s.d.; * p<0.0001. Scale bar: 10 µm 
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Figure 21. Ultrastructural analysis of ER morphology in neurons expressing D-REEP1-P19R 
mutated form. (a) representative EM images of third instar larva brains (n,nucleus; m, mitochondria; 
white arrows indicate ER). (b) 3D rendering of D-REEP1-P19R localization in lipid droplets labeled with 
BODIPY 493/503 in Drosophila nervous system. Inset shows higher-magnification images 
 
4.8 EXPRESSION IN DROSOPHILA OF H-REEP1-A132V 
PATHOLOGICAL MUTATION  
H-REEP1 p.A132V (c.C395T) is an unpublished missense mutation (M. L. 
Mostacciuolo group), localized at the C-terminal part of the protein. We generated 
transgenic lines for tissue specific expression of H-REEP1-A132V in Drosophila. The 
A132V substitution was introduced in the H-REEP1 cDNA by site directed mutagenesis 
and its presence was confirmed by sequence analysis. To generate Drosophila 
transgenic lines, the mutated cDNA was introduced in the pUAST vector, in frame at 
the 5’ terminal with a HA tag. 
To study the effects of in vivo H-REEP1-A132V we expressed the mutant protein under 
the control of the ubiquitous driver line tubulin-Gal4. Confocal microscopy analysis of 
third instar larvae showed a different subcellular localization of H-REEP1-A132V 
compared to D-REEP1-P19R. Surprisingly, H-REEP1-A132V, co-localized 
predominantly with the ER marker KDEL-GFP, as the wild type protein. 
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Immunocytochemistry analysis did not show any alteration of ER morphology. (Figure 
22). However, because resolution of confocal analysis is limited we decided to analyze 
in more detail the ultrastructure of the ER by electron microscopy. We performed 
electron microscopy and visualized the neuronal ER in the brains of third instar larvae 
expressing H-REEP1-A132V. EM analysis did not show any significant alteration of 
ER length profiles or morphology (Figure 23). 
Our ongoing work is focused on understanding if H-REEP1-A132V pathological 
mutation can affect the lipid metabolism in the nervous system as the expression of D-
REEP1-P19R mutated form. Moreover, we will try to study if H-REEP1-A132V can 
perturb the cytoskeleton dynamics in vivo, since this mutation is located at the C-
terminal part of H-REEP1, a domain important for microtubule binding. 
 
Figure 22. In vivo expression of H-REEP-A132V. Immunocytochemistry of wall muscle and nervous 
system axons of third instar larvae expressing H-REEP-A132V with anti HAto label H-REEP1-A132V 
expression GFP-KDEL to label the ER marker. The mutated form of H-REEP1 co-localize with ER 
marker GFP-KDEL. Scale bar 20µm 
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Figure 23. Ultrastructural analysis of ER morphology in neurons expressing H-REEP1-A132V 
mutated form. Representative EM images of third instar larva brains (n,nucleus; m, mitochondria; white 
arrows indicate ER) 
 
4.9 HUMAN AND DROSOPHILA REEP1 EXPRESSION IN 
MAMMALIAN CELL CULTURE 
We generated different construct for expression in cell system of wild type and 
pathological mutant forms of human and Drosophila REEP1, for in vitro studies. cDNA 
of H-REEP1 and D-REEP1 were cloned in the pcDNA3.1 plasmid in frame with HA 
tag and/or Myc tag. This constructs were expressed in HeLa cells, mammalian cell line 
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derived from a cervical carcinoma. As in vivo, D-REEP1 protein localized with ER 
marker PDI while the mutated form D-REEP1-P19R localized principally with lipid 
droplets marker BODIPY (Figure 25). Expression of H-REEP1 protein in HeLa cells 
showed a reticular pattern and partially co-localized with the microtubule marker, 
acetylated tubulin. The data obtained for H-REEP1 are in accordance with previous 
studies. The expression in HeLa cells of the mutated form H-REEP1-A132V displayed 
a phenotype very similar to the wild type form, confirming the reticular localization 
observed in vivo (Figure 24). 
In addition, we generated another pathological mutation H-REEP1 p.D56N (Goizet et 
al. 2011) at the second trans-membrane domain. H-REEP1 p.D56N was inserted in H-
REEP1 cDNA by site-directed mutagenesis and its presence was confirmed by sequence 
analysis. We expressed H-REEP1-D56N in HeLa cells. Surprisingly we observed that 
H-REEP1-D56N displayed the same phenotype as H-REEP1-P19R, it co-localized 
predominantly with the LDs marker BODIPY (Figure 24). 
Using a bio-informatics approach, we analyzed how this pathological mutation could 
affect the REEP1 protein. We used two different software: Membrane topology 
software, available on the European Molecular Biology Laboratory (EMBL) protein 
prediction web site, that evaluates the hydrophobicity of the amino acid sequence and 
compares it with the hydrophobicity of polytopic proteins whose membrane topologies 
have been solved (Rost, Fariselli, and Casadio 1996); Hidden Markov Model for 
Topology Prediction (HMMTOP) based on the principle that membrane topology of 
trans-membrane proteins is determined by the divergence of amino acid composition of 
sequence segments (Tusnády and Simon 1998). Based on these studies, these software 
confirmed the presence of two transmembrane domain for wild type REEP1 protein and 
suggested that in REEP1 p.P19R, the substitution of the proline with arginine leads to a 
total loss of the first trans-membrane domain.,while for the REEP1 p.D56N, substitution 
of aspartic acid with asparagine could increase the loop between the two trans-
membranes. 
Therefore pathological mutations of H-REEP1 localized in the trans-membrane domain, 
affect the hydrophobicity levels of the protein. Since two different pathological 
mutations of H-REEP1 change the localization of the protein from the ER to LDs, we 
wanted to investigate which region is necessary and sufficient for lipid droplets sorting. 
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For this purpose we used mutational analysis. We generated two truncated forms of H-
REEP1 protein fused in frame with HA tag at the N-terminal. One truncated form was 
generated without the first transmembrane domanin, while in the second truncated form 
lacked the first transmembrane and the loop between two trans-membranes domain. The 
cDNA of truncated from was cloned in pcDNA3.1 plasmid and expressed in HeLa cells. 
Similarly to the H-REEP-P19R and H-REEP1-D56N, truncated forms localized on the 
lipid droplets surface of HeLa cells (Figure 24). Therefore, probably the second trans-
membrane domain contains the necessary information for lipid droplet targeting, 
whereas the first tranmembrane domain contains information for ER targeting. 
 
 
 
Figure 24. Subcellular localization changes of H-REEP1 in response to point mutations. HeLa cells 
were transfected with HA tagged human REEP1 and double labeled with BODIPY 493/503 to display 
lipid droplets (green) and anti HA tag to label REEP1 (red). Pathological mutation affecting the first 
(P19R) or the second transmembrane domain (D56N) causes a relocation of REEP1 around lipid droplets 
structures. In addition deletion of the first transmembrane domain (HREEP1 ∆TM1) has the same 
phenotype of point mutations P19R and D56N. Scale bar: 20 µm 
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Figure 25. In vitro localization of D-REEP1 confirms the in vivo phenotype. HeLa cells were 
transfected with Myc tagged D-REEP1 and double labeled with BODIPY 493/503 to display lipid 
droplets (green) and anti Myc tag to label D-REEP1 (red). Scale bar: 20 µm. Inset shows higher-
magnification images 
 
4.10 H-REEP1 IS CAPABLE OF HOMO-OLIGOMERIZATION 
Co-immunoprecipitation (co-IP) is a common technique used for the identification of 
protein interaction. An antibody for the protein of interest, linked to a support matrix, is 
incubated with a cell extract to allow the antibody to bind the protein in solution. The 
antibody/antigen complex will then be pulled out of the sample by precipitation: this 
will physically isolates, from the rest of the sample, the protein of interest and other 
proteins potentially bound to it (co-immunoprecipitation). Finally, components of the 
immunocomplex (antibody, antigen and co-immunprecipitated proteins) are analyzed by 
SDSPAGE and Western blot. To test if H-REEP1 could self-assemble, HeLa cells were 
co-transfected with H-REEP1-HA and H-REEP1-Myc constructs. Lysates prepared 
from these cells were immunoprecipitated using anti-Myc antibodies. The 
immunoprecipitate was analyzed by western blotting with both anti-Myc and anti-HA 
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antibodies. The presence of both Myc and HA signals in the immunoprecipitate (phase 
P) showed that immunoprecipitation of H-REEP1-Myc pulled down also H-REEP1-HA 
thus suggesting that H-REEP1 molecules are capable of homo-oligomerization (Figure 
26).  
To analyze if H-REEP1-P19R protein could oligomerize with the wild type protein 
HeLa cells were separately transfected with H-REEP1-P19R-HA and H-REEP1-Myc 
constructs and processed  as described above for the wild type form. Myc signal was 
observed in the immunoprecipiate while the HA signal was detected at the supernatant 
phase suggesting that probably the mutated form of D-REEP1-P19R is not capable of 
holigomerization (Figure 26). 
 
Figure 26. Wild type but not H-REEP1-P19R self-associates. Lysates from HeLa cells co-transfected 
with wild type DREEP1-Myc and DREEP1-HA or DREEP1
P19R
-Myc and DREEP1
P19R
-HA were 
immunoprecipitated and analyzed by western blot. L, lysate; S, supernatant; P, pellet 
. 
4.11 REEP1 MEMBRANE TOPOLOGY  
H-REEP1 protein, belongs to the REEP/DP1/Yop1p superfamily, has two trans-
membrane domains and a TB2/DP1/HAV22 or known as deleted in polyposis domain. 
The DP1/Yop1 family proteins members contain two hydrophobic segments. It has been 
proposed that each of these hydrophobic segments form a “wedge” shape within the 
lipid bilayer, while the hydrophilic segments are found in the cytoplasm. Previous 
studies have reported that the C-terminal part of H-REEP1 protein is oriented toward 
the cytosol. Based on this finding we wanted to verify the orientation of D-REEP1 
protein as well as the orientation of the N-terminal part of H-REEP1. To test this 
hypothesis we used a protease protection assay. This technique entails the isolation of 
intact membrane vesicles from cellular fraction and the subsequent protease treatment 
of the sample. The vesicle membrane will shelter from proteases digestion the part of 
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the protein not exposed to the cytoplasm. Membrane vesicles were prepared from HeLa 
cells transfected with D-REEP1 and cells transfected with H-REEP1. Transfected cells 
were homogenized in the absence of detergent and fragmented membranes were 
vesiculated by sonication. Proteinase K was added to the intact vesiculated membranes 
which were then analyzed by western blotting. Loss of HA and Myc signals detection in 
western blots of membrane fraction treated with proteinase K (P2K) indicates that the 
amino- and carboxy-terminal parts of REEP1 are digested and therefore face the 
cytoplasm. calnexin was used as an internal control. The antibody used to recognize 
calnexin, binds the N-terminal of the protein that is located in the luminal part of the 
ER. Therefore after protease digestion the N-terminal of calnexin located inside the 
vesiculated membrane is protected, and the antibody signal can be detected by western 
blot analysis (Figure 27).  
 
Figure 27. Membrane topology of human and Drosphila REEP1. (a) Western blot analysis of 
vesciculated membrane fractions from H-REEP1 and D-REEP1 expressing cell homogenates, treated 
with Proteinase K. L, lysate; S, supernatant; P1, pellet. P2K, pellet treated with proteasi. (b) Schematic 
presentation of the possible membrane insertion of H-REEP1 and D-REEP1 
 
 
 
 
 
 
 
 4. RESULTS 
 
98 
 
 
 
 
 
 
 
 
 
 
 5. DISCUSSION 
 
99 
5. DISCUSSION 
Mutations of SPG31 gene, which encodes REEP1 protein, are responsible for a 
dominant form of Hereditary Spastic Paraplegia (HSP), a clinically and genetically 
heterogeneous group of inherited disorders mainly characterized by progressive lower 
limb spasticity and weakness. The mechanisms by which REEP1 mutations produce 
dominant HSP in humans are controversial. The broad mutational spectrum observed 
(small frameshift mutations, but nonsense, missense, microRNA target site alterations 
and deletion) has suggested that the molecular mechanism is likely to be 
haploinsufficiency; however, other mechanisms have been postulated to be possible. 
The REEP1 gene encodes an ER integral membrane protein, with two transmembrane 
domains and a TB2/DP1/HVA22 domain with unknown function (Züchner et al. 2006). 
REEP1 protein belongs to the REEP/DP1/YOP1 superfamily of ER-shaping proteins 
and is thought to interact with other two HSP related proteins, atlastin-1 and spastin to 
coordinate ER shaping. However, the precise molecular function of REEP1 remain to 
be elucidated  
We used Drosophila melanogaster as a model organism to study REEP1 function in 
vivo. The anatomy and development of Drosophila nervous system has been extensively 
characterized and many tools are available to study the neuronal functions (i.e. synaptic 
transmission). Although morphologically distinct and of lower complexity, the D. 
melanogaster CNS comprises the same basic building blocks as the mammalian CNS. 
These properties, apart from making the fruit fly a good model in neurobiological 
research, make D. melanogaster a powerful tool for the understanding of the genetic 
and molecular mechanisms of neural development and for the investigation of the 
neural basis of behavior. Flies also provide a platform for rapid drug discovery because 
it is easy to generate large numbers of genetically identical animals that can be tested. 
Therefore, fly models have been generated to understand the pathological mechanism of 
neurodegeneration. Our group has successfully generated Drosophila models for other 
two HSP-linked proteins, atlastin (SPG3) and spastin (SPG4). Creation of this 
Drosophila HSP models elucidated the cellular function of atlastin and spastin proteins. 
Moreover, the use of active compound, vimblastine, rescued the neuronal defects 
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caused by Drosophila spastin loss of function. Thus Drosophila melanogaster is a 
powerful genetic tool for studying HSP pathogenic mechanism. 
We identified as the homolog of H-REEP1, the CG42678 gene (D-REEP1) in 
Drosophila. The presence in the Drosophila genome of a high conserved H-REEP1 
ortholog combined with the wide array of experimental tools available makes 
Drosophila a valuable system to investigate the function of D-REEP1. Domain 
sequence analysis showed that all of the H-REEP1 protein domains are conserved in the 
Drosophila homolog.  
Experiments we carried out in vivo and in vitro have shown that D-REEP1 modulates 
ER membrane morphology and affects the lipid droplets (LDs) size and number. D-
REEP1 localizes in the ER membrane, consistent with the localization of the human 
ortholog. In vitro subcellular fractionation studies have shown that D-REEP1 associates 
with ER membranes. D-REEP1, as H-REEP1, includes two hydrophobic regions 
conferring a “wedge” shape to the protein that shallowly inserts into the outer lipid 
monolayer of the ER membrane. Both the N- and the C-terminus are hydrophilic and 
protrude into the cytoplasm. Protease protection studies employing proteinase K 
treatment of intact vesiculated membranes from HeLa cells overexpressing D-REEP1 
demonstrated that the D-REEP1 C-terminus and N-terminus faces the cytoplasm. These 
data are consistent with membrane topology model proposed for the REEP1-4 
subfamily (Park et al. 2010).  
Loss of D-REEP1 in vivo resulted in an elongation of the ER profiles in Drosophila 
neurons. This data suggest an evolutionary conserved function of D-REEP1 with the 
role of REEP1-4 subfamily members in ER membrane shaping and network formation 
(Park et al, 2010). 
Our in vivo data suggest an unexpected role for D-REEP1 in controlling lipid storage in 
Drosophila. Analysis of Drosophila D-REEP1 mutants showed reduced lipid storage in 
the fat body, the adipose tissue of Drosophila, and a reduced quantity of total 
triglycerides in third instar larvae compared to wild type controls. The lipid droplets 
storage defects of D-REEP1 loss of function in vivo are similar to those observed in 
Drosophila dSeipin mutant (SPG20) (Tian et al.2011). Seipin, an integral ER protein, 
has been established as an important factor in regulating LDs dynamics, particularly 
size and distribution.  
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Moreover we detected a decrease of lipid droplets number in the nervous system of D-
REEP1 mutants, a phenotype that has not been reported previously. In eukaryotes, lipid 
droplets are believed to arise primarily from the ER, where the enzymes that synthesize 
neutral lipids reside, and in yeast it has been shown that they invariably arise from or 
close to the ER (Buhman et al. 2001). Alteration of ER profile length in D-REEP1 loss 
of function mutant could change the dynamics of ER network formation. Due to the 
strong connection between ER and LDs formation we suggest that loss of REEP1 may 
affect lipid droplets biogenesis, even though, further experimental data are needed to 
characterize in more detail this mechanism. 
In vivo overexpression of D-REEP1 did not lead to obvious alterations of ER 
morphology but decreased the LDs size in the nervous system. DP1/Yop1p proteins 
deform the lipid bilayer into high-curvature tubules through hydrophobic insertion and 
scaffolding mechanisms by occupying more space in the outer than the inner leaflet of 
the ER lipid bilayer via their membrane-inserted, double-hairpin hydrophobic domains 
(Hu et al. 2009). Such “shaping” activity is found in all REEPs and in REEP1, it is 
determined by residues 37 to 76. This domain represents also an intramembrane site of 
interaction with numerous other ER-resident proteins. Based on protein family 
similarity and structure conservation the small size LDs phenotype can be due to higher 
curvature induced by the overexpression of D-REEP1.  
To better clarify the pathological mechanism of REEP1 we generated transgenic lines 
expressing mutant forms of the protein. We over expressed in vivo the p.P19R mutation, 
a missense mutation that falls in a highly conserved region of REEP1 N-terminal 
region. The D-REEP1-P19R mutant form localized predominantly in the surface of LDs 
in vivo. There are two classes of proteins that can reside in the lipid droplets; the first 
class are proteins without integral hydrophobic domain that could be targeted to LDs 
from the cytosol, like Perilipin (Garcia et al. 2003). The second group is characterized 
by the presence of an integral hydrophobic domain that is most likely inserted in the 
ER, allowing the protein to laterally diffuse into forming droplets, like oleosin (Hope, 
Denis J Murphy, and McLauchlan 2002). Access to the LD surface is only possible 
because these proteins lack hydrophilic domains on the luminal side of the membrane, 
as such domains could not be accommodated in the hydrophobic LD core. 
Bioinformatics analysis of D-REEP1-P19R sequence suggested that this mutation 
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within the first transmembrane domain altered its hydrophobicity. Therefore this amino 
acid substitution could change the topology of REEP1 from two to one transmembrane 
domain and facilitate the insertion in the LDs membrane. In addition, because the 
second transmembrane domain is not affected by this mutation, it may contain the 
necessary information for LD targeting. The overexpression of D-REEP-P19R in vivo 
determined an increase of LDs size and a decrease of their number in Drosophila 
nervous system. Two hypotheses could explain the increase of lipid droplets size. 
According to the first one, LDs can locally synthesize the neutral lipids or the neutral 
lipids can be targeted and delivered from the ER through LD-ER contact sites 
(Moessinger et al. 2011). The second possibility is that increase of LDs size is caused 
by fusion of smaller, existing LDs. Therefore the D-REEP1-P19R may increase the LD-
ER contact size or facilitates the LDs fusion. Additionally, an increase association of 
some proteins with LDs, can vary the concentration of proteins located on LDs 
membrane and affect the neutral lipids turnover and as consequence the LDs size. An 
analogous condition is verified when ADRP protein is expressed in HEK 293 cells. 
ADRP-mediated repression of TAG (triacylglycerol) hydrolysis in HEK293 cells 
correlated with a dramatic loss of ATGL from lipid droplets and caused an increase in 
TAG mass (Listenberger et al. 2007). The in vivo subcellular location of D-REEP1-
P19R, almost exclusively in LDs surface, could modify the concentration of existing 
LDs proteins leading to a defective lipid droplet turnover. However, these hypothesises 
need to be confirmed by experimental data. 
The p.P19R mutation cause an autosomal dominat form of HSP, with early onset 
associated to a severe phenotype. The haploinsufficiency mechanism is generally 
considered to give rise to HSP-causing REEP1 mutations (Beetz et al. 2008). Different 
subcellular localization of mutated protein could sustain the haploinsufficiency 
mechanism. However, based on the in vivo phenotypes of D-REEP1-P19R, an increase 
of LDs size and a reduction of LDs number in the nervous system, suggest that probably 
this mutation do not lead to haploinsufficiency but it rather leads to a dominat negative 
effect, interfering with the wild type protein function. 
To understand the pathological mechanism of REEP1 mutations, we decided to analyze 
the phenotypes of humanized flies. Transgenic flies for H-REEP1-A132V pathological 
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mutation were generated. Expression of H-REEP-A132V, in Drosophila showed an 
association of the protein predominantly with the ER marker GFP-KDEL. In vivo, 
overexpression of H-REEP-A132V did not lead to obvious changes in the ER 
morphology. This difference observed between the severity of the phenotypes caused by 
REEP-A132V and that caused by REEP1-P19R could somehow reflect the weaker 
clinical phenotype of the patient carrying the D-REEP1-A132V. In fact, this patient 
displayed a non severe form of HSP with slight symptoms and late onset. Our ongoing 
work is focused on understanding if A132V pathological mutation can affect the lipid 
metabolism in Drosophila nervous system or the cytoskeleton dynamics in vivo.  
To further confirm the involvement of REEP1 in lipid droplets regulation we evaluated 
the expression of both human and Drosophila REEP1 protein in mammalian cell 
culture. Expression of H-REEP1 in HeLa cells displayed a reticular pattern and tubular 
ER, in agreement with previous reports. In addition, expression of H-REEP1-D56N, a 
pathological mutation within the second transmembrane domain, showed a localization 
on LDs surface. Bioinformatics analysis showed that D56N mutation similarly to the 
P19R mutation changes the hydrophobicity profile, and increases the length of the 
hydrophilic loop between the transmembrane domains. In addition, expression in HeLa 
cells of H-REEP1 lacking the first transmembrane domain (∆TM1 REEP1), showed a 
localization of the truncated protein with LDs membrane. The data obtained in vivo by 
the expression of D-REEP1-P19R and the expression of ∆TM1 REEP1support the idea 
that the second transmembrane domain has the necessary informations for LDs 
targeting. Moreover, these data imply that the alteration of aminoacid hydrophobicity 
could changes the membrane insertion of REEP1 protein leading to a different 
subcellular localization and produce a dysfunctional protein. 
Our study demonstrated that the Drosophila ortholog D-REEP1, is also involved in 
coordinating the ER morphology. Moreover our data demonstrate that loss of function 
and missense mutations of REEP1 affect lipid droplets biogenesis and lipid droplets 
size. The fundamental link between ER and lipid droplets biogenesis imply that a 
dysfunction of the ER or a modification of ER morphology can directly affect LDs 
formation or metabolism. Nevertheless further studies will be necessary to analyze in 
more detail and to confirm the function D-REEP1 in order to establish its direct 
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involvement in the regulation of LDs size or biogenesis. Identification of the precise 
molecular mechanism of REEP1 function may contribute to a better understanding of 
neuronal degeneration in Hereditary Spastic Paraplegia. 
Recently, other genes/proteins involved in HSP, erlin2 (SPG18), seipin (SPG17) and 
spartin (SPG20), have been implicated in alteration of synthesis and metabolism of 
lipids and sterols. (Eastman, Yassaee, and Bieniasz 2009; Edwards et al. 2009; Hooper 
et al. 2010).Within the last few years, genetic and functional data on HSP genes and 
proteins have opened an entirely novel perspective on the pathogenesis of this disease, 
strongly indicating that alterations in cholesterol, fatty acid, phospholipid, and 
sphingolipid metabolism play a relevant role in the pathogenesis of HSP. Lipid 
composition is important for the organization of neuronal membranes, affects crucial 
processes such as exocytosis and ion channel function, and contributes to the formation 
of membrane domains. Furthermore, there is increasing evidence that lipids provide an 
important role as signaling mediators and effectors (Piomelli, Astarita, and Rapaka 
2007). Remarkably, disturbances in lipid metabolism offer the unprecedented 
opportunity to identify biomarkers for HSP and to design novel therapeutic strategies 
aiming at restoring the normal lipid profile. 
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